CN102174579A - Reducible and biodegradable comb type high polymer gene vector and preparation method of same - Google Patents
Reducible and biodegradable comb type high polymer gene vector and preparation method of same Download PDFInfo
- Publication number
- CN102174579A CN102174579A CN 201110020684 CN201110020684A CN102174579A CN 102174579 A CN102174579 A CN 102174579A CN 201110020684 CN201110020684 CN 201110020684 CN 201110020684 A CN201110020684 A CN 201110020684A CN 102174579 A CN102174579 A CN 102174579A
- Authority
- CN
- China
- Prior art keywords
- hours
- asp
- polymer
- molecular weight
- comb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 74
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 239000013598 vector Substances 0.000 title description 5
- 229920006317 cationic polymer Polymers 0.000 claims abstract description 66
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 239000013256 coordination polymer Substances 0.000 claims abstract description 5
- 229920002521 macromolecule Polymers 0.000 claims abstract 3
- 229920002873 Polyethylenimine Polymers 0.000 claims description 150
- 238000006243 chemical reaction Methods 0.000 claims description 53
- -1 propargyl carbonylimidazole compound Chemical class 0.000 claims description 49
- 206010011732 Cyst Diseases 0.000 claims description 42
- 208000031513 cyst Diseases 0.000 claims description 42
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 40
- 239000003960 organic solvent Substances 0.000 claims description 39
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 37
- 125000000304 alkynyl group Chemical group 0.000 claims description 36
- 239000002904 solvent Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 229920000805 Polyaspartic acid Polymers 0.000 claims description 21
- 108010064470 polyaspartate Proteins 0.000 claims description 21
- 238000003786 synthesis reaction Methods 0.000 claims description 20
- 150000001345 alkine derivatives Chemical group 0.000 claims description 19
- 230000015572 biosynthetic process Effects 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 19
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 16
- 150000001540 azides Chemical class 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 12
- 239000003999 initiator Substances 0.000 claims description 12
- 239000000178 monomer Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims description 9
- 229940099500 cystamine Drugs 0.000 claims description 9
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- BLFRQYKZFKYQLO-UHFFFAOYSA-N 4-aminobutan-1-ol Chemical compound NCCCCO BLFRQYKZFKYQLO-UHFFFAOYSA-N 0.000 claims description 8
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 claims description 8
- 238000010560 atom transfer radical polymerization reaction Methods 0.000 claims description 8
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 claims description 8
- 229920002401 polyacrylamide Polymers 0.000 claims description 8
- 239000005267 main chain polymer Substances 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 238000010526 radical polymerization reaction Methods 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- VHRYZQNGTZXDNX-UHFFFAOYSA-N methacryloyl chloride Chemical compound CC(=C)C(Cl)=O VHRYZQNGTZXDNX-UHFFFAOYSA-N 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- CSTIZSQKHUSKHU-UHFFFAOYSA-N 2-azidoethanamine Chemical compound NCCN=[N+]=[N-] CSTIZSQKHUSKHU-UHFFFAOYSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 claims 1
- 102100024304 Protachykinin-1 Human genes 0.000 claims 1
- 101800003906 Substance P Proteins 0.000 claims 1
- 238000001890 transfection Methods 0.000 abstract description 24
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 10
- 230000003013 cytotoxicity Effects 0.000 abstract description 10
- 230000004962 physiological condition Effects 0.000 abstract 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 50
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 23
- 239000000243 solution Substances 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 230000004048 modification Effects 0.000 description 17
- 238000012986 modification Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 239000002994 raw material Substances 0.000 description 16
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 238000005227 gel permeation chromatography Methods 0.000 description 14
- 238000001228 spectrum Methods 0.000 description 13
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 238000007306 functionalization reaction Methods 0.000 description 10
- 108060001084 Luciferase Proteins 0.000 description 9
- 239000005089 Luciferase Substances 0.000 description 9
- 238000012637 gene transfection Methods 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000002329 infrared spectrum Methods 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 125000002355 alkine group Chemical group 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- 150000003852 triazoles Chemical group 0.000 description 7
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 6
- 238000001476 gene delivery Methods 0.000 description 6
- 238000000569 multi-angle light scattering Methods 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 5
- 101710141544 Allatotropin-related peptide Proteins 0.000 description 4
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 4
- VHJLVAABSRFDPM-IMJSIDKUSA-N L-1,4-dithiothreitol Chemical compound SC[C@H](O)[C@@H](O)CS VHJLVAABSRFDPM-IMJSIDKUSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 4
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- LFKYBJLFJOOKAE-UHFFFAOYSA-N imidazol-2-ylidenemethanone Chemical compound O=C=C1N=CC=N1 LFKYBJLFJOOKAE-UHFFFAOYSA-N 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 229920002246 poly[2-(dimethylamino)ethyl methacrylate] polymer Polymers 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- YUWBVKYVJWNVLE-UHFFFAOYSA-N [N].[P] Chemical compound [N].[P] YUWBVKYVJWNVLE-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000011246 composite particle Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000002466 imines Chemical class 0.000 description 3
- 238000004172 nitrogen cycle Methods 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007142 ring opening reaction Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- RKBAZLYWJAIMCH-UHFFFAOYSA-N 1-aminoethane-1,1-dithiol Chemical compound CC(N)(S)S RKBAZLYWJAIMCH-UHFFFAOYSA-N 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 231100000086 high toxicity Toxicity 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000010550 living polymerization reaction Methods 0.000 description 2
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229920000962 poly(amidoamine) Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- QVCOXWYMPCBIMH-UHFFFAOYSA-N prop-2-ynyl carbamate Chemical compound NC(=O)OCC#C QVCOXWYMPCBIMH-UHFFFAOYSA-N 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- XLSNRCSDLXPFKF-UHFFFAOYSA-N 1-(1h-imidazol-2-yl)but-3-yn-1-one Chemical compound C#CCC(=O)C1=NC=CN1 XLSNRCSDLXPFKF-UHFFFAOYSA-N 0.000 description 1
- SEOVUYCETFJOGT-UHFFFAOYSA-N 1-azidopropan-1-ol Chemical compound CCC(O)N=[N+]=[N-] SEOVUYCETFJOGT-UHFFFAOYSA-N 0.000 description 1
- BDXJANJAHYKTMI-UHFFFAOYSA-N 2,3,4,5-tetramethyl-1h-pyrrole Chemical class CC=1NC(C)=C(C)C=1C BDXJANJAHYKTMI-UHFFFAOYSA-N 0.000 description 1
- NULDEVQACXJZLL-UHFFFAOYSA-N 2-(2-aminoethyldisulfanyl)ethylazanium;chloride Chemical compound Cl.NCCSSCCN NULDEVQACXJZLL-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 101100438060 Arabidopsis thaliana TZF6 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- PONGSGZDIYJXOW-UHFFFAOYSA-N C(C)N.C(C)SSCC.C(C#C)NC(O)=O Chemical compound C(C)N.C(C)SSCC.C(C#C)NC(O)=O PONGSGZDIYJXOW-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 229920000891 common polymer Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N monoethyl amine Natural products CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- UKODFQOELJFMII-UHFFFAOYSA-N pentamethyldiethylenetriamine Chemical compound CN(C)CCN(C)CCN(C)C UKODFQOELJFMII-UHFFFAOYSA-N 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- OCAAZRFBJBEVPS-UHFFFAOYSA-N prop-2-enyl carbamate Chemical compound NC(=O)OCC=C OCAAZRFBJBEVPS-UHFFFAOYSA-N 0.000 description 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Images
Landscapes
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Polyamides (AREA)
Abstract
本发明公开了一种可还原降解的梳型高分子基因载体及其制备方法。结构如下式所示:式中CP为低分子量阳离子聚合物,分子量在600-30000之间,F1和F2为可以互相反应的基团,并且F1或者F2含有双硫键,M为聚合物的主链单元结构,n=10-500;m<n,m=0-400,l=0-800;l、m、n为整数。本发明的梳型高分子基因载体细胞毒性小,在生理条件下能很好地绑定和复合基因DNA,进入细胞内由于细胞内的还原环境可较快断裂而释放出所载基因。结果表明其比25kDa PEI具有更高的转染效率和更低的细胞毒性。并且制备方法简单,结构控制容易。
The invention discloses a reductively degradable comb-shaped polymer gene carrier and a preparation method thereof. The structure is as follows: In the formula, CP is a low-molecular-weight cationic polymer with a molecular weight between 600-30000, F1 and F2 are groups that can react with each other, and F1 or F2 contains a disulfide bond, M is the main chain unit structure of the polymer, and n= 10-500; m<n, m=0-400, l=0-800; l, m, n are integers. The comb-shaped macromolecule gene carrier of the present invention has low cytotoxicity, can well bind and compound gene DNA under physiological conditions, and can release the contained gene due to the rapid breakage of the reducing environment in the cell when it enters the cell. The results showed that it had higher transfection efficiency and lower cytotoxicity than 25kDa PEI. Moreover, the preparation method is simple, and the structure control is easy.
Description
技术领域technical field
本发明涉及一种可还原降解的梳型高分子基因载体及其制备方法,属于基因治疗领域。The invention relates to a reductively degradable comb-shaped polymer gene carrier and a preparation method thereof, belonging to the field of gene therapy.
背景技术Background technique
人类基因组工程草案的完成,使人们更好的理解基因和疾病的关系。截止到2008年,已经有1400多临床病例,利用基因来纠正遗传缺损或治疗后天性疾病(http://www.wiley.co.uk/genmed/clinical/)。遗传学领域已经确定了很多具有治疗和预防疾病潜力的基因,但基因运送体系的进展却有限,是目前基因治疗的瓶颈。运送基因的载体主要包括病毒载体和非病毒载体。因为转染效率高,病毒载体被首先应用于基因治疗的临床研究;然而,由于存在安全隐患和复杂昂贵的制备过程,限制了其应用和推广。因此,研究开发高效安全的非病毒基因载体具有非常重要的意义。The completion of the human genome project draft has enabled people to better understand the relationship between genes and diseases. As of 2008, there have been more than 1,400 clinical cases, using genes to correct genetic defects or treat acquired diseases (http://www.wiley.co.uk/genmed/clinical/). The field of genetics has identified many genes with the potential to treat and prevent diseases, but the progress of gene delivery systems is limited, which is the bottleneck of gene therapy at present. Gene delivery vectors mainly include viral vectors and non-viral vectors. Because of the high transfection efficiency, viral vectors were first applied in the clinical research of gene therapy; however, their application and promotion were limited due to safety hazards and complicated and expensive preparation process. Therefore, it is of great significance to research and develop efficient and safe non-viral gene vectors.
阳离子高分子聚合物是目前研究较多的非病毒基因载体,包括聚赖氨酸(polylysine,PLL),聚乙烯亚胺(polyethylenimine,PEI),壳聚糖及其衍生物,聚酰胺-胺(polyamidoamine,PAMAM)树形高分子和聚甲基丙烯酸酯阳离子衍生物等。但传统的高分子基因载体由于相对低的转染效率和高的毒性而不能用于临床,例如不可降解的阳离子高分子在细胞内累积会导致很高的毒性等。高分子基因载体转染效率和毒性一般随分子量的增加而提高。例如,以PEI为载体的DNA复合物在0.6-70kDa内随着分子量的增大其转染效率增大[Godbey W.T.,et al.,J.Biomed.Mater.Res.1999,45,268],PEI的细胞毒性也随着分子量的增大而提高。有研究报道分子量低于1.8kDa的PEI几乎没有转染效果,比较适宜作基因载体的PEI分子量范围大致为11.9-70kDa[Godbey W.T.;Wu K.K.;Mikos A.G.Size matters:molecular weight affects the efficiency of poly(ethylenimine)as a genedelivery vehicle.J.Biomed.Mater.Res.1999,45,268],最常用的分子量是25kDa,因此,在大多数研究中都是选用25KDa的支化PEI作为参照标准。Cationic macromolecular polymers are non-viral gene carriers that have been studied more at present, including polylysine (polylysine, PLL), polyethyleneimine (polyethyleneimine, PEI), chitosan and its derivatives, polyamide-amine ( polyamidoamine, PAMAM) dendrimers and polymethacrylate cationic derivatives, etc. However, traditional polymer gene carriers cannot be used clinically due to relatively low transfection efficiency and high toxicity. For example, the accumulation of non-degradable cationic polymers in cells will lead to high toxicity. The transfection efficiency and toxicity of polymer gene vectors generally increase with the increase of molecular weight. For example, the DNA complex with PEI as the carrier increases its transfection efficiency with the increase of molecular weight within 0.6-70kDa [Godbey W.T., et al., J.Biomed.Mater.Res.1999,45,268], The cytotoxicity of PEI also increases with the increase of molecular weight. It has been reported that PEI with a molecular weight lower than 1.8kDa has almost no transfection effect, and the molecular weight range of PEI suitable as a gene carrier is roughly 11.9-70kDa [Godbey W.T.; Wu K.K.; Mikos A.G. Size matters: molecular weight affects the efficiency of poly( ethyleneimine) as a genedelivery vehicle.J.Biomed.Mater.Res.1999,45,268], the most commonly used molecular weight is 25kDa, therefore, in most studies, the branched PEI of 25KDa is selected as the reference standard.
为了解决聚合物分子量对载体转染效率和毒性的矛盾影响,Lee课题组首先报道了引入可还原降解的双硫键,与活泼氨基反应交联分子量为0.8kDa的PEI制得高分子量的PEI衍生物[MA.Gosselin,W-J.Guo,R.J.Lee,Efficient genetransfer using reversibly cross-linked low molecular weight polyethylenimine,Bioconjugate Chem.12(2001)989-994],该PEI衍生物具有较高转染效率和很低的毒性。类似的研究在我们的前一篇发明专利[中国专利申请公布号:CN101812178A]中已论述,这类PEI衍生物的主要缺点是交联度不易控制,得到的聚合物溶解性不好,含有的微凝胶必须用柱子除去,工艺复杂,产率低[R.Deng,Y.N Yue,F.Jin,Y.C.Chen,HF Kung,M.C.M.Lin,C.Wu,Revisit the complexation of PEI andDNA-How to make low cytotoxic and highly efficient PEI gene transfectionnon-viral vectors with a controllable chain length and structure?J.Control.Release140(2009)40-46.]。In order to solve the contradictory effect of polymer molecular weight on vector transfection efficiency and toxicity, Lee's research group first reported the introduction of reductively degradable disulfide bonds, which reacted with active amino groups to cross-link PEI with a molecular weight of 0.8 kDa to obtain high molecular weight PEI derivatives. [MA.Gosselin, W-J.Guo, R.J.Lee, Efficient genetransfer using reversibly cross-linked low molecular weight polyethyleneimine, Bioconjugate Chem.12 (2001) 989-994], the PEI derivative has higher transfection efficiency and very low toxicity. Similar studies have been discussed in our previous invention patent [Chinese patent application publication number: CN101812178A]. The main disadvantage of this type of PEI derivatives is that the degree of crosslinking is not easy to control, and the resulting polymer has poor solubility and contains The microgel must be removed with a column, the process is complicated, and the yield is low Cytotoxic and highly efficient PEI gene transfection non-viral vectors with a controllable chain length and structure? J. Control. Release 140 (2009) 40-46.].
本发明将含可反应端基的低分子量聚阳离子通过侧基反应制备含双硫键的梳型高分子量阳离子聚合物,该类制备方法简单,不会产生交联。制得的聚合物可在还原环境中快速降解成较低分子量的聚合物,同时具有较高基因转染效率和较低细胞毒性。The invention prepares a comb-shaped high molecular weight cationic polymer containing a disulfide bond by reacting a low-molecular-weight polycation containing a reactive terminal group through a side group reaction. The preparation method of this type is simple and does not produce crosslinking. The prepared polymers can be rapidly degraded into lower molecular weight polymers in a reducing environment, and at the same time have higher gene transfection efficiency and lower cytotoxicity.
发明内容Contents of the invention
本发明所要解决的技术问题在于提供一种具有较高基因转染效率和较低细胞毒性、同时不会交联的梳型高分子基因载体及其制备方法。The technical problem to be solved by the present invention is to provide a comb-shaped polymer gene carrier with high gene transfection efficiency and low cytotoxicity and no cross-linking and a preparation method thereof.
本发明所提供的高分子基因载体是一种含双硫键改性的梳形阳离子聚合物,结构如下式所示:The polymer gene carrier provided by the present invention is a comb-shaped cationic polymer modified with a disulfide bond, and its structure is shown in the following formula:
式中CP为低分子量阳离子聚合物,分子量在600-30000之间,F1和F2为可以互相反应的基团,并且F1或者F2含有双硫键,M为聚合物的主链单元结构,n=10-500;m<n,m=0-400,l=0-800;l、m、n为整数。In the formula, CP is a low-molecular-weight cationic polymer with a molecular weight between 600-30000, F1 and F2 are groups that can react with each other, and F1 or F2 contains a disulfide bond, M is the main chain unit structure of the polymer, and n= 10-500; m<n, m=0-400, l=0-800; l, m, n are integers.
n取值范围为10-500,主要通过制备主链聚合时所加的单体和引发剂的比例来控制。l取值范围为0-800,主要通过制备主链聚合时所加的单体原料的组成或者侧链改性的原料组成来控制。m<n,m取值范围为0-400,主要通过加入侧链改性的原料组成来控制。The value range of n is 10-500, which is mainly controlled by the ratio of monomer and initiator added when preparing the main chain polymerization. The value range of l is 0-800, which is mainly controlled by the composition of the monomer raw materials added during the main chain polymerization or the composition of the side chain modified raw materials. m<n, the value range of m is 0-400, which is mainly controlled by adding side chain modified raw material composition.
原料低分子量阳离子聚合物的分子量范围在600-30000之间,若用PDE,其分子量在2000-30000之间为优,如用PEI,其分子量在600-5000之间为优。The molecular weight range of the raw material low molecular weight cationic polymer is between 600-30000. If PDE is used, the molecular weight is preferably between 2000-30000. If PEI is used, the molecular weight is preferably between 600-5000.
更具体的方案可以是:A more specific solution could be:
CP为线形聚甲基丙烯酸-2-N,N-二甲氨基乙酯(L-PDE-N3)或者聚乙烯亚胺(PEI)。CP is linear polymethacrylate-2-N,N-dimethylaminoethyl ester (L-PDE-N 3 ) or polyethyleneimine (PEI).
聚合物的主链单元结构为聚天冬氨基酸衍生物、聚甲基丙烯酰胺或者聚丙烯酰胺类衍生物。The main chain unit structure of the polymer is polyaspartic acid derivative, polymethacrylamide or polyacrylamide derivative.
本发明还提供上述高分子基因载体的制备方法,包含如下步骤:The present invention also provides a preparation method of the above-mentioned polymer gene carrier, comprising the following steps:
(1)合成带一个反应端基F1的低分子量(low molecular-weight)阳离子聚合物CP-F1;(1) synthesis of low molecular weight (low molecular-weight) cationic polymer CP-F1 with a reactive end group F1;
(2)合成主链聚合物,其侧链含有可与F1端基反应的基团F2,并且F1或者F2含有双硫键,如右式所示: (2) Synthesize the main chain polymer, its side chain contains the group F2 that can react with the F1 end group, and F1 or F2 contains a disulfide bond, as shown in the right formula:
(3)将上述两种聚合物混合反应、纯化,制得含双硫键的梳型阳离子聚合物。(3) The above two polymers are mixed, reacted and purified to prepare a comb-shaped cationic polymer containing disulfide bonds.
进一步的方案是:F1为含叠氮基团,F2为含双硫键和炔基基团;或F1为含双硫键和炔基基团,F2为含叠氮基团。A further scheme is: F1 is an azide-containing group, F2 is a disulfide bond-containing and alkynyl group; or F1 is a disulfide bond-containing and alkynyl group, and F2 is an azide-containing group.
功能化的低分子量(low molecular-weight)阳离子聚合物CP-F1的合成方法为普通自由基聚合法或者可控活性聚合法,或者通过商业化的低分子量阳离子聚合物的改性。The functionalized low molecular weight (low molecular-weight) cationic polymer CP-F1 is synthesized by ordinary free radical polymerization or controlled living polymerization, or by modification of commercial low molecular weight cationic polymer.
所述的主链聚合物,其至少一部分侧链含有与F1端基可反应的基团F2,并且F1或者F2含有双硫键,合成方法包括但不限于普通自由基聚合法或者可控活性聚合法,或者通过商业化的聚合物的侧链改性或者合成聚合物再侧链改性。The main chain polymer, at least a part of its side chain contains a group F2 that can react with the end group of F1, and F1 or F2 contains a disulfide bond. The synthesis method includes but is not limited to ordinary free radical polymerization or controlled living polymerization method, either by side chain modification of commercial polymers or side chain modification of synthetic polymers.
当本发明所提供的高分子基因载体中,带反应端基F1的低分子量阳离子聚合物CP-F1为叠氮端基功能化的线形聚甲基丙烯酸-2-N,N-二甲氨基乙酯(poly(2-(dimethylamino)ethyl methacrylate),PDE),主链聚合物为侧链含双硫键和炔基基团的聚天冬氨基酸衍生物时,In the polymer gene carrier provided by the present invention, the low-molecular-weight cationic polymer CP-F1 with the reactive end group F1 is a linear polymethacrylic acid-2-N, N-dimethylaminoethylene functionalized with an azide end group. Ester (poly(2-(dimethylamino)ethyl methacrylate), PDE), when the main chain polymer is a polyaspartic acid derivative with a disulfide bond and an alkynyl group in the side chain,
具体的制备方法如下:Concrete preparation method is as follows:
(1)含一个叠氮端基功能化的线形聚甲基丙烯酸-2-N,N-二甲氨基乙酯(L-PDE-N3)的制备方法:采用原子转移自由基聚合法,控制引发剂和单体的比例,制得分子量在2000-30000之间的L-PDE-N3;(1) The preparation method of linear polymethacrylic acid-2-N, N-dimethylaminoethyl ester (L-PDE-N 3 ) containing an azide end group functionalization: adopt atom transfer radical polymerization method, control The ratio of initiator and monomer is used to prepare L-PDE-N 3 with molecular weight between 2000-30000;
(2)侧链含双硫键和炔基基团的聚天冬氨基酸衍生物的制备方法:将炔丙酯羰基咪唑化合物和胱胺按摩尔比0.5-1.5∶1加入有机溶剂中,在20-60℃下搅拌反应2-48小时,纯化得到(烯丙基氨基甲酸酯乙基)二硫乙胺化合物(PPA-cyst);再将(烯丙基氨基甲酸酯乙基)二硫乙胺化合物(PPA-cyst)和聚琥珀酰亚胺(PSI)按摩尔比0.2-2∶1加入溶剂中,在20-70℃下搅拌反应2-48小时,合成制得侧链含双硫键和炔基基团的聚天冬氨基酸衍生物P(Asp-ss-Al);(2) The preparation method of the polyaspartic acid derivative that side chain contains disulfide bond and alkynyl group: add propargyl carbonylimidazole compound and cystamine in molar ratio 0.5-1.5: 1 in the organic solvent, in 20 The reaction was stirred at -60°C for 2-48 hours, and purified to obtain (allyl carbamate ethyl) dithioethylamine compound (PPA-cyst); then (allyl carbamate ethyl) disulfide Ethylamine compound (PPA-cyst) and polysuccinimide (PSI) are added to the solvent at a molar ratio of 0.2-2:1, stirred and reacted at 20-70°C for 2-48 hours, and the side chain disulfide-containing Polyaspartic acid derivative P(Asp-ss-Al) of bond and alkynyl group;
(3)将上述的L-PDE-N3和P(Asp-ss-Al)按叠氮端基与炔基的摩尔比0.5-3∶1溶于有机溶剂或者水中或者水和有机溶剂的混合物中,在20-80℃下进行反应1-48小时,若产物还有未开环的结构存在,则再加入过量的N,N-二甲基丙二胺或者N,N-二甲基乙二胺,或者乙醇胺、丙醇胺、丁醇胺或者戊醇胺,反应24小时,得到含双硫键的梳型阳离子聚合物P(Asp-ss-Al-Az-PDE),其结构示意图可为下式:(3) The above-mentioned L-PDE-N 3 and P(Asp-ss-Al) are dissolved in an organic solvent or water or a mixture of water and an organic solvent according to the molar ratio of azide end group to alkynyl group of 0.5-3:1 , react at 20-80°C for 1-48 hours, if the product still has an unopened ring structure, then add excess N,N-dimethylpropylenediamine or N,N-dimethylethylene Diamine, or ethanolamine, propanolamine, butanolamine or pentanolamine, reacted for 24 hours to obtain a comb-shaped cationic polymer P(Asp-ss-Al-Az-PDE) containing a disulfide bond, and its structural representation can be is the following formula:
当本发明所提供的高分子载体中,低分子量阳离子聚合物CP-F1为叠氮端基功能化的分子量在600-5000之间的聚乙烯亚胺(PEI)衍生物,其中重均分子量在600-5000之间的聚乙烯亚胺的结构示意图为:In the polymer carrier provided by the present invention, the low-molecular-weight cationic polymer CP-F1 is a polyethyleneimine (PEI) derivative with a molecular weight between 600-5000 functionalized by an azide end group, wherein the weight-average molecular weight is between The schematic structure of polyethyleneimine between 600-5000 is:
主链聚合物为可降解的聚天冬氨基酸衍生物,其侧链含双硫键和炔基基团时,具体的制备方法如下:When the main chain polymer is a degradable polyaspartic acid derivative, and its side chain contains disulfide bonds and alkynyl groups, the specific preparation method is as follows:
(1)叠氮端基功能化的聚乙烯亚胺的制备方法:将叠氮丙酯羰基咪唑化合物和重均分子量在600-5000之间的聚乙烯亚胺PEI按摩尔比0.3-1.1∶1溶于有机溶剂中,在25-60℃下搅拌反应2-24小时,减压除去溶剂,得到含咪唑小分子的叠氮端基功能化的聚乙烯亚胺,其中的每个聚乙烯亚胺含叠氮端基的数量为0.3-1.1;(1) The preparation method of polyethyleneimine functionalized with azide end group: the molar ratio of propyl azidocarbonylimidazole compound and polyethyleneimine PEI with a weight average molecular weight between 600-5000 is 0.3-1.1:1 Soluble in an organic solvent, stir and react at 25-60°C for 2-24 hours, remove the solvent under reduced pressure to obtain azide-end functionalized polyethyleneimine containing imidazole small molecules, each of which is polyethyleneimine The number of azide-containing end groups is 0.3-1.1;
(2)侧链含双硫键和炔基基团的聚天冬氨基酸衍生物的制备方法:将炔丙酯羰基咪唑化合物和胱胺按摩尔比0.5-1.5∶1加入有机溶剂中,在20-60℃下搅拌反应2-48小时,纯化得到(烯丙基氨基甲酸酯乙基)二硫乙胺化合物([(propargylcarbamate)ethyl]-dithioethylamine,PPA-cyst);再将(烯丙基氨基甲酸酯乙基)二硫乙胺化合物(PPA-cyst)和聚琥珀酰亚胺(PSI)按摩尔比0.2-2∶1加入溶剂中,在20-70℃下搅拌反应2-48小时,合成制得侧链含炔基基团摩尔百分比在15%-100%的聚天冬氨基酸衍生物P(Asp-ss-Al);(2) The preparation method of the polyaspartic acid derivative that side chain contains disulfide bond and alkynyl group: add propargyl carbonylimidazole compound and cystamine in molar ratio 0.5-1.5: 1 in the organic solvent, in 20 The reaction was stirred at -60°C for 2-48 hours, and the (allyl carbamate ethyl) dithioethylamine compound ([(propargylcarbamate) ethyl]-dithioethylamine, PPA-cyst) was obtained after purification; Carbamate ethyl) dithioethylamine compound (PPA-cyst) and polysuccinimide (PSI) are added to the solvent at a molar ratio of 0.2-2:1, and the reaction is stirred at 20-70°C for 2-48 hours , synthesize and prepare a polyaspartic acid derivative P(Asp-ss-Al) with a molar percentage of alkynyl group in the side chain of 15%-100%;
(3)将上述的P(Asp-ss-Al)溶于有机溶剂,若其还有未开环的结构存在,则先加入过量的N,N-二甲基丙二胺或者N,N-二甲基乙二胺,或者乙醇胺、丙醇胺、丁醇胺或者戊醇胺,反应24小时,再将上述的叠氮端基功能化的聚乙烯亚胺按叠氮端基与炔基的摩尔比0.5-3∶1溶于有机溶剂或者水中或者水和有机溶剂的混合物中,在20-80℃下进行反应1-48小时,得到含双硫键的梳型阳离子聚合物P(Asp-ss-Al-Az-PEI),其结构示意图可为:(3) Dissolve the above-mentioned P(Asp-ss-Al) in an organic solvent. If there is still an unopened ring structure, add excess N,N-dimethylpropylenediamine or N,N- Dimethylethylenediamine, or ethanolamine, propanolamine, butanolamine or pentanolamine, reacted for 24 hours, and then the above-mentioned polyethyleneimine functionalized with azide end group according to the ratio of azide end group and alkynyl group The molar ratio is 0.5-3:1 dissolved in an organic solvent or water or a mixture of water and an organic solvent, and reacted at 20-80°C for 1-48 hours to obtain a comb-shaped cationic polymer P(Asp- ss-Al-Az-PEI), its structure diagram can be:
当本发明所提供的高分子载体中,低分子量阳离子聚合物CP-F1为含一个叠氮端基的分子量在2000-30000之间的聚甲基丙烯酸-2-N,N-二甲基胺乙酯(L-PDE-N3);主链为聚合物侧链含双硫键和炔基基团的甲基丙烯酰胺类或者丙烯酰胺类衍生物时,具体的制备方法如下:In the polymer carrier provided by the present invention, the low molecular weight cationic polymer CP-F1 is polymethacrylic acid-2-N,N-dimethylamine with a molecular weight between 2000-30000 containing an azide end group Ethyl ester (L-PDE-N 3 ); when the main chain is methacrylamide or acrylamide derivatives containing disulfide bonds and alkynyl groups in the polymer side chain, the specific preparation method is as follows:
(1)含一个叠氮端基功能化的线形聚甲基丙烯酸-2-N,N-二甲氨基乙酯(L-PDE-N3)的制备方法:采用原子转移自由基聚合法,控制引发剂和单体的比例,制得分子量在2000-30000之间的L-PDE-N3;(1) The preparation method of linear polymethacrylic acid-2-N, N-dimethylaminoethyl ester (L-PDE-N 3 ) containing an azide end group functionalization: adopt atom transfer radical polymerization method, control The ratio of initiator and monomer is used to prepare L-PDE-N 3 with molecular weight between 2000-30000;
(2)侧链含双硫键和炔基基团的聚甲基丙烯酰胺或者聚丙烯酰胺类衍生物的制备方法:将炔丙酯羰基咪唑化合物和胱胺按摩尔比0.5-1.5∶1加入有机溶剂中,在20-60℃下搅拌反应2-48小时,纯化得到(烯丙基氨基甲酸酯乙基)二硫乙胺化合物(PPA-cyst);再将(烯丙基氨基甲酸酯乙基)二硫乙胺化合物(PPA-cyst)和甲基丙烯酰氯或者丙烯酰氯反应纯化,再加入引发剂如偶氮二异丁腈AIBN和溶剂,在50-80℃下搅拌反应2-24小时,或通过ATRP聚合合成制得侧链含双硫键和炔基基团的聚甲基丙烯酰胺类衍生物P(PPA-cyst-Mam)或者聚丙烯酰胺类衍生物P(PPA-cyst-Am);(2) The preparation method of polymethacrylamide or polyacrylamide derivatives containing disulfide bonds and alkynyl groups in the side chain: adding propargyl carbonylimidazole compound and cystamine in a molar ratio of 0.5-1.5:1 In an organic solvent, stir and react at 20-60°C for 2-48 hours, and purify to obtain (allyl carbamate ethyl) dithioethylamine compound (PPA-cyst); then (allyl carbamate Ethyl ester) dithioethylamine compound (PPA-cyst) reacts with methacryloyl chloride or acryloyl chloride for purification, then adds an initiator such as azobisisobutyronitrile AIBN and a solvent, and stirs the reaction at 50-80°C 2- 24 hours, or synthesized by ATRP polymerization to prepare polymethacrylamide derivatives P(PPA-cyst-Mam) or polyacrylamide derivatives P(PPA-cyst-Mam) containing disulfide bonds and alkynyl groups in the side chain -Am);
(3)将上述的L-PDE-N3和P(PPA-cyst-MAm)或者P(PPA-cyst-Am)按叠氮端基与炔基的摩尔比0.5-3∶1溶于有机溶剂或者水中或者水和有机溶剂的混合物中,在20-80℃下进行反应1-48小时,纯化得到含双硫键的梳型阳离子聚合物P(PPA-cyst-MAm-PDE),其结构示意图为:(3) Dissolve the above-mentioned L-PDE-N 3 and P(PPA-cyst-MAm) or P(PPA-cyst-Am) in an organic solvent according to the molar ratio of azide end group to alkynyl group of 0.5-3:1 Or in water or a mixture of water and organic solvents, react at 20-80°C for 1-48 hours, and purify to obtain a comb-shaped cationic polymer P(PPA-cyst-MAm-PDE) containing a disulfide bond, its structure schematic diagram for:
当本发明所提供的高分子载体中,低分子量功能化阳离子聚合物CP-F1为含双硫键和炔基端基的分子量在600-5000之间的聚乙烯亚胺衍生物;主链聚合物为可降解的聚天冬氨基酸衍生物,其侧链含叠氮基团。具体的步骤如下:In the polymer carrier provided by the present invention, the low-molecular-weight functionalized cationic polymer CP-F1 is a polyethyleneimine derivative with a molecular weight between 600-5000 containing a disulfide bond and an alkynyl end group; the main chain is polymerized The compound is a degradable polyaspartic acid derivative with an azide group in its side chain. The specific steps are as follows:
(1)炔端基功能化的聚乙烯亚胺PEI-(PPA-cyst)的制备方法:将炔丙酯羰基咪唑化合物和胱胺按摩尔比0.5-1.5∶1加入有机溶剂中,在20-60℃下搅拌反应2-48小时,纯化得到(烯丙基氨基甲酸酯乙基)二硫乙胺化合物(PPA-cyst);再将(烯丙基氨基甲酸酯乙基)二硫乙胺化合物(PPA-cyst)与1,1’-羰基二咪唑按摩尔比0.4-0.75∶1加入有机溶剂中,在20-70℃下搅拌反应2-48小时,纯化得到(烯丙基氨基甲酸酯乙基)二硫乙基1-碳酰胺咪唑化合物(PPA-cyst-CI);将化合物PPA-cyst-CI和重均分子量在600-5000之间的聚乙烯亚胺按摩尔比0.2-1.1∶1溶于有机溶剂中,在20-60℃下搅拌反应2-48小时,减压除去溶剂,得到含咪唑小分子的炔端基功能化的聚乙烯亚胺,其中的每个聚乙烯亚胺含炔端基的数量取值范围为0.2-1.1(绝大多数的每个聚乙烯亚胺含炔端基为1个或者0个,聚乙烯亚胺PEI含炔端基的平均数量值为0.2-1.1);(1) The preparation method of the polyethyleneimine PEI-(PPA-cyst) of alkyne end group functionalization: add propargyl ester carbonylimidazole compound and cystamine in molar ratio 0.5-1.5: 1 in the organic solvent, in 20- Stir the reaction at 60°C for 2-48 hours, and obtain (allyl carbamate ethyl) dithioethylamine compound (PPA-cyst) after purification; then (allyl carbamate ethyl) dithioethylamine Amine compound (PPA-cyst) and 1,1'-carbonyldiimidazole molar ratio 0.4-0.75:1 are added to the organic solvent, stirred and reacted at 20-70°C for 2-48 hours, and purified to obtain (allylaminomethyl Ethyl ester) dithioethyl 1-carboxamide imidazole compound (PPA-cyst-CI); Compound PPA-cyst-CI and polyethyleneimine with a weight average molecular weight between 600-5000 in molar ratio 0.2- 1.1:1 dissolved in an organic solvent, stirred and reacted at 20-60°C for 2-48 hours, and the solvent was removed under reduced pressure to obtain a polyethylenimine functionalized with an alkyne end group containing a small molecule of imidazole, in which each polyethyleneimine The number of alkyne-containing end groups of imines ranges from 0.2 to 1.1 (the vast majority of each polyethyleneimine contains 1 or 0 alkyne-containing end groups, and the average number of alkyne-containing end groups of polyethyleneimine PEI is 0.2-1.1);
(2)侧链含叠氮基团的聚天冬氨基酸衍生物的制备方法:将2-叠氮乙胺和聚琥珀酰亚胺(PSI)按摩尔比0.4-2∶1加入溶剂中,在20-70℃下搅拌反应2-200小时,若产物还有未开环的结构存在,则再加入过量的N,N-二甲基丙二胺或者N,N-二甲基乙二胺,或者乙醇胺、丙醇胺、丁醇胺或者戊醇胺,反应24小时,合成制得侧链含叠氮基团的聚天冬氨基酸衍生物P(Asp-Az);(2) The preparation method of the polyaspartic acid derivative that side chain contains azide group: 2-azidoethylamine and polysuccinimide (PSI) are added in the solvent in molar ratio 0.4-2: 1, in Stir and react at 20-70°C for 2-200 hours, if the product still has an unopened ring structure, then add excess N,N-dimethylpropylenediamine or N,N-dimethylethylenediamine, Or ethanolamine, propanolamine, butanolamine or pentanolamine, and react for 24 hours to synthesize a polyaspartic acid derivative P(Asp-Az) containing an azide group in the side chain;
(3)将上述的炔端基功能化的聚乙烯亚胺PEI-(PPA-cyst)和P(Asp-Az)按炔基端基与叠氮的摩尔比0.5-3∶1溶于有机溶剂或者水中或者水和有机溶剂的混合物中,在20-80℃下进行反应1-96小时,得到含双硫键的改性还原敏感性梳型高分子量阳离子聚合物P(Asp-Az-Al-ss-PEI),其结构示意图可为下列之一:(3) The polyethyleneimine PEI-(PPA-cyst) and P(Asp-Az) functionalized by the above-mentioned alkyne end group are dissolved in an organic solvent according to the molar ratio of the alkyne end group to azide of 0.5-3:1 Or in water or a mixture of water and an organic solvent, the reaction is carried out at 20-80 ° C for 1-96 hours to obtain a modified reduction-sensitive comb-shaped high-molecular-weight cationic polymer P(Asp-Az-Al- ss-PEI), its structure diagram can be one of the following:
本发明的还原敏感性梳型高分子阳离子聚合物,可以与外源基因结合,用作基因载体。The reduction-sensitive comb-type high molecular cationic polymer of the present invention can be combined with exogenous genes and used as a gene carrier.
所述基因载体为用于人体或者动植物细胞基因传导的载体,用合适的复合方法,可以与目标基因(DNA或者RNA)复合形成稳定的复合物小颗粒。将该复合物与人体或者动物细胞共同培养,可以将目标基因(DNA或者RNA)带入人体或者动物细胞内释放,并转染表达,用于人体基因治疗和动植物的基因传导。The gene carrier is a carrier used for gene transduction of human body or animal and plant cells, and can be compounded with the target gene (DNA or RNA) to form a stable complex small particle by using a suitable compounding method. The complex is co-cultivated with human or animal cells, and the target gene (DNA or RNA) can be brought into human or animal cells for release, transfected and expressed, and used for human gene therapy and gene transduction of animals and plants.
本发明的含双硫键改性的还原敏感性梳型高分子作为基因载体时,引入聚乙二醇、靶向基团和/或可以交联的组分。引入聚乙二醇可以降低生物体系(比如人体)对基因载体材料的排异性,大大降低蛋白质、细胞和病菌在基因载体材料表面的吸附,还能降低被肾脏清除的速率(因为它的体积较大)。可引入靶向基团如叶酸和抗体,提高基因载体系统的靶向传递特性,靶向进入肿瘤细胞后由于细胞内还原环境会很快降解释放出所载的基因药物。可引入少量可以交联的组分,在该改性的梳型高分子阳离子聚合物装载基因药物后进行交联,可提高装载基因药物体系的稳定性。When the modified reduction-sensitive comb polymer containing disulfide bonds of the present invention is used as a gene carrier, polyethylene glycol, targeting groups and/or components that can be cross-linked are introduced. The introduction of polyethylene glycol can reduce the rejection of biological systems (such as the human body) to gene carrier materials, greatly reduce the adsorption of proteins, cells and bacteria on the surface of gene carrier materials, and also reduce the rate of clearance by the kidneys (because its volume is relatively small) big). Targeting groups such as folic acid and antibodies can be introduced to improve the targeted delivery characteristics of the gene carrier system. After targeting into tumor cells, the intracellular reducing environment will quickly degrade and release the loaded gene drug. A small amount of components that can be cross-linked can be introduced, and cross-linking can be carried out after the modified comb-type high molecular cationic polymer is loaded with gene drugs, which can improve the stability of the system loaded with gene drugs.
本发明的高分子聚合物具有生物还原可降解的特性。在细胞外能很好地绑定和复合基因DNA,进入细胞内由于细胞内的还原环境可较快断裂成近似原料低分子量的聚合物而释放出所载基因,因而同时具有较高基因转染效率和较低细胞毒性,是一种很有应用前景的高分子基因载体。The high molecular polymer of the present invention has the characteristic of bioreduction and degradability. It can bind and compound gene DNA very well outside the cell, and enter the cell because the reducing environment in the cell can quickly break into a polymer with a low molecular weight similar to the raw material and release the contained gene, so it has a high gene transfection at the same time High efficiency and low cytotoxicity, it is a promising polymer gene carrier.
本发明的制备方法是以低分子量阳离子聚合物为主要原料,利用高选择性的反应如点击化学反应,制得最终产物。优点在于方法简单,不会产生交联。由于使用了高选择性的反应如点击化学,结构控制容易,反应消失的带正电基团很少或者没有,带正电基团如氨基利用率很高。The preparation method of the invention uses the low molecular weight cationic polymer as the main raw material, and utilizes a highly selective reaction such as a click chemical reaction to prepare the final product. The advantage is that the method is simple and does not produce cross-linking. Due to the use of highly selective reactions such as click chemistry, the structure control is easy, the positively charged groups that disappear in the reaction are few or no, and the utilization rate of positively charged groups such as amino groups is high.
附图说明Description of drawings
图1为本发明合成的(A)单炔端基功能化的聚乙烯亚胺PEI-(PPA-cyst)(实施例4,每个聚乙烯亚胺分子平均含0.33个炔基团)在CDCl3,(B)P(Asp-Az)0.65(Asp-EA)0.35(实施例6)在D2O和(C)含双硫键改性的梳型高分子量阳离子聚合物P(Asp-Az-Al-ss-PEI)(Asp-EA)0.35(实施例11)在D2O的核磁氢谱图Fig. 1 is (A) monoalkyne end group functionalized polyethyleneimine PEI-(PPA-cyst) (embodiment 4, each polyethyleneimine molecule contains 0.33 alkyne groups on average) in CDCl 3 , (B) P(Asp-Az) 0.65 (Asp-EA) 0.35 (Example 6) in D 2 O and (C) comb-shaped high molecular weight cationic polymer P(Asp-Az) modified with disulfide bonds -Al-ss-PEI)(Asp-EA) 0.35 (Example 11) in D 2 O NMR spectrum
图2为本发明合成的含双硫键改性的梳型高分子量阳离子聚合物P(PPA-cyst-MAm-PDE)-1在加入50mmol/L DTT前(A)后(B)及L-PDE-N3-2(C)的GPC色谱图(实施例12)Fig. 2 is the comb type high molecular weight cationic polymer P(PPA-cyst-MAm-PDE)-1 that contains disulfide bond modification of the synthesis of the present invention before (A) after adding 50mmol/L DTT (B) and L- The GPC chromatogram of PDE-N 3 -2 (C) (embodiment 12)
图3为动态光散射检测梳型高分子量阳离子聚合物P(PPA-cyst-MAm-PDE)与DNA复合粒子粒径在加入DTT前后随时间的变化(实施例12)Fig. 3 is that dynamic light scattering detects comb type high molecular weight cationic polymer P (PPA-cyst-MAm-PDE) and DNA composite particle particle size change with time before and after adding DTT (embodiment 12)
图4为本发明合成的含双硫键改性的梳型高分子量阳离子聚合物P(Asp-Az-Al-ss-PEI)(Asp-EA)0.67,P(Asp-Az-Al-ss-PEI)(Asp-EA)0.35和P(Asp-Az-Al-ss-PEI)及参照聚合物PEI 25kDa对293T的细胞毒性比较(实施例13,图示数据为4孔平行实验的平均值和标准方差)。Fig. 4 is the comb type high molecular weight cationic polymer P(Asp-Az-Al-ss-PEI)(Asp-EA) 0.67 containing disulfide bond modification synthesized by the present invention, P(Asp-Az-Al-ss- PEI) (Asp-EA) 0.35 and P (Asp-Az-Al-ss-PEI) and reference polymer PEI 25kDa to the cytotoxicity comparison of 293T (
图5为本发明合成含双硫键改性梳型高分子量聚阳离子P(Asp-ss-Al-Az-PDE)-1和P(Asp-ss-Al-Az-PDE)-2(实施例8),低分子量聚合物L-PDE-N3-1,线形高分子量的HMPDE及对照聚合物PEI 25kDa对293T的细胞毒性比较(实施例13,图示数据为4孔平行实验的平均值和标准方差)。Fig. 5 is that the present invention synthesizes and contains disulfide bond modified comb type high molecular weight polycation P(Asp-ss-Al-Az-PDE)-1 and P(Asp-ss-Al-Az-PDE)-2 (embodiment 8), low molecular weight polymer L-PDE-N 3 -1, the HMPDE of linear high molecular weight and contrast polymer PEI 25kDa are to the cytotoxicity comparison of 293T (
图6为本发明合成含双硫键改性的梳型高分子量阳离子聚合物P(Asp-Az-Al-ss-PEI)(Asp-EA)0.67,P(Asp-Az-Al-ss-PEI)(Asp-EA)0.35和P(Asp-Az-Al-ss-PEI)在不同的聚合物/DNA质量比时对293T细胞在无血清存在时的荧光素酶转染表达(实施例14,图示数据为3孔平行实验的平均值和标准方差)。Fig. 6 is that the present invention synthesizes the cationic polymer P(Asp-Az-Al-ss-PEI) (Asp-EA) 0.67 of the comb type high molecular weight modified containing disulfide bond, P(Asp-Az-Al-ss-PEI )(Asp-EA) 0.35 and P(Asp-Az-Al-ss-PEI) were expressed to 293T cells by luciferase transfection in the absence of serum at different polymer/DNA mass ratios (Example 14, The data shown are the mean and standard deviation of 3 well parallel experiments).
图7为本发明合成的含双硫键改性的梳型高分子量阳离子聚合物P(Asp-ss-Al-Az-PDE)-1和P(Asp-ss-Al-Az-PDE)-2,低分子量聚合物L-PDE-N3-1和线形高分子量的HMPDE在不同的聚合物/DNA质量比时对293T细胞在无血清存在时的荧光素酶转染表达(PEI 25kDa与DNA的氮磷比为10,实施例14,图示数据为3孔平行实验的平均值和标准方差)。Fig. 7 is the comb type high molecular weight cationic polymer P(Asp-ss-Al-Az-PDE)-1 and P(Asp-ss-Al-Az-PDE)-2 containing disulfide bond modification synthesized by the present invention , low-molecular-weight polymer L-PDE-N 3 -1 and linear high-molecular-weight HMPDE were expressed in luciferase transfection in 293T cells in the absence of serum at different polymer/DNA mass ratios (PEI 25kDa and DNA The ratio of nitrogen to phosphorus is 10, in Example 14, the data shown are the mean and standard deviation of 3 well parallel experiments).
图8为本发明合成的含双硫键改性的梳型高分子量阳离子聚合物P(Asp-ss-Al-Az-PDE)-1和P(Asp-ss-Al-Az-PDE)-2,低分子量聚合物L-PDE-N3-1在不同的聚合物/DNA质量比时对HeLa细胞在无血清存在时的荧光素酶转染表达(PEI 25kDa与DNA的氮磷比为10,实施例14,图示数据为3孔平行实验的平均值和标准方差)。Fig. 8 is the comb-shaped high molecular weight cationic polymer P(Asp-ss-Al-Az-PDE)-1 and P(Asp-ss-Al-Az-PDE)-2 containing disulfide bond modification synthesized by the present invention , the low molecular weight polymer L-PDE-N 3 -1 was expressed by luciferase transfection in HeLa cells in the absence of serum at different polymer/DNA mass ratios (the nitrogen-phosphorus ratio of PEI 25kDa to DNA was 10, Example 14, the illustrated data are the mean and standard deviation of 3 well parallel experiments).
图9为本发明合成的含双硫键改性的梳型高分子量阳离子聚合物P(Asp-ss-Al-Az-PDE)-1和P(Asp-ss-Al-Az-PDE)-2,低分子量聚合物L-PDE-N3-1在不同的聚合物/DNA质量比时对293T细胞在有血清存在时的荧光素酶转染表达(PEI 25kDa与DNA的氮磷比为10,实施例15,图示数据为3孔平行实验的平均值和标准方差)。Fig. 9 is the comb-type high molecular weight cationic polymer P(Asp-ss-Al-Az-PDE)-1 and P(Asp-ss-Al-Az-PDE)-2 containing disulfide bond modification synthesized by the present invention , the low molecular weight polymer L-PDE-N 3 -1 was expressed by luciferase transfection in 293T cells in the presence of serum at different polymer/DNA mass ratios (the nitrogen-phosphorus ratio of PEI 25kDa to DNA was 10, Example 15, the illustrated data are the mean and standard deviation of 3 well parallel experiments).
具体实施方式Detailed ways
以下通过实施例进一步解释本发明,但它们不是对权利要求的限制。The present invention is further explained by the following examples, but they are not limiting to the claims.
通过核磁共振谱测试改性梳型高分子阳离子聚合物的结构,通过凝胶渗透色谱(GPC)测试聚合物的分子量。The structure of the modified comb-type polymer cationic polymer was tested by nuclear magnetic resonance spectroscopy, and the molecular weight of the polymer was tested by gel permeation chromatography (GPC).
实施例1(烯丙基氨基甲酸酯乙基)二硫乙胺((propargyl carbamate)ethyldisulfide ethylamine,PPA-cyst)和(烯丙基氨基甲酸酯乙基)二硫乙基1-碳酰胺咪唑((propargyl carbamate)ethyl disulfide ethyl 1-carbamide-imidazole,PPA-cyst-CI)的合成Embodiment 1 (allyl carbamate ethyl) dithioethylamine ((propargyl carbamate) ethyldisulfide ethylamine, PPA-cyst) and (allyl carbamate ethyl) dithioethyl 1-carbon amide Synthesis of imidazole ((propargyl carbamate) ethyl disulfide ethyl 1-carbamide-imidazole, PPA-cyst-CI)
(烯丙基氨基甲酸酯乙基)二硫乙胺((propargyl carbamate)ethyl disulfideethylamine,PPA-cyst)的合成:根据文献[X.L.Jiang,M.C.Lok,W.E.Hennink,Degradable-Brushed pHEMA-pDMAEMA synthesized via ATRP and click chemistryfor gene delivery,Bioconjugate Chem.18(2007)2077-2084]通过炔丙醇和1,1’-羰基二咪唑合成炔丙酯羰基咪唑(propargyl ester ofcarbonyl-imidazole,PPA-CI)。先将胱胺盐酸盐脱盐,称4.40克的胱胺和3.47克炔丙酯羰基咪唑溶于50毫升氯仿,室温下搅拌反应24小时,除去溶剂,加入80毫升磷酸二氢钠溶液(pH 4.0)溶解,用乙醚萃取3次,将所得下层水相部分调节pH到9.0,再用40毫升的乙酸乙酯萃取3次,合并有机相,用40毫升pH=9磷酸钠溶液洗一次,得到的有机相用无水硫酸镁干燥,过滤,减压蒸馏得到黄色油状液体1.9克,产率为35%。1H-NMR in CDCl3:δ(ppm)2.45(s,1H,CH≡C),2.75(m,4H,S-CH2-C),2.98(m,2H,NH2-CH2-C),3.50(m,2H,NH-CH2-C),4.37(b,2H,NH2-C),4.64(s,2H,O-CH2-C≡C),5.58(s,1H,NH-C=O)。该反应的氯仿换成无活泼质子的其它有机溶剂如二氯甲烷,丙酮,四氢呋喃,DMF也同样进行并可得到类似的结果。(Allyl carbamate ethyl) dithioethylamine ((propargyl carbamate) ethyl disulfideethylamine, PPA-cyst) synthesis: According to the literature [XLJiang, MCLok, WEHennink, Degradable-Brushed pHEMA-pDMAEMA synthesized via ATRP and click chemistry for gene delivery, Bioconjugate Chem.18 (2007) 2077-2084] synthesize propargyl ester of carbonyl-imidazole (PPA-CI) by propargyl alcohol and 1,1'-carbonyldiimidazole. First desalt cystamine hydrochloride, weigh 4.40 grams of cystamine and 3.47 grams of propargyl carbonylimidazole in 50 milliliters of chloroform, stir and react at room temperature for 24 hours, remove the solvent, add 80 milliliters of sodium dihydrogen phosphate solution (pH 4.0 ) was dissolved, extracted 3 times with diethyl ether, adjusted the pH of the obtained lower aqueous phase to 9.0, then extracted 3 times with 40 ml of ethyl acetate, combined the organic phases, washed once with 40 ml of pH=9 sodium phosphate solution, and obtained The organic phase was dried with anhydrous magnesium sulfate, filtered, and distilled under reduced pressure to obtain 1.9 g of a yellow oily liquid with a yield of 35%. 1 H-NMR in CDCl 3 : δ(ppm) 2.45(s, 1H, CH≡C), 2.75(m, 4H, S-CH 2 -C), 2.98(m, 2H, NH 2 -CH 2 -C ), 3.50 (m, 2H, NH-CH 2 -C), 4.37 (b, 2H, NH 2 -C), 4.64 (s, 2H, O-CH 2 -C≡C), 5.58 (s, 1H, NH-C=O). The chloroform of this reaction is replaced with other organic solvents without active protons such as dichloromethane, acetone, tetrahydrofuran, and DMF is also carried out and similar results can be obtained.
(烯丙基氨基甲酸酯乙基)二硫乙基1-碳酰胺咪唑((propargylcarbamate)ethyl disulfide ethyl 1-carbamide-imidazole,PPA-cyst-CI)合成:称取1,1’-羰基二咪唑(CDI)3.94克溶于40ml氯仿中,将上述的PPA-cyst 1.9克滴入CDI的氯仿溶液中,常温反应4h,反应液由浑浊变为透明。加水洗涤三次,有机相用无水硫酸镁干燥,过滤,减压蒸馏得白色固体PPA-cyst-CI 1.9克,产率为71%。1H-NMR in CDCl3:δ(ppm)2.49(s,1H,CH≡C),2.78(t,2H,S-CH2-CH2-NH-COO),3.00(t,2H,S-CH2-CH2-NH-CON),3.50(m,2H,-OCO-NH-CH2-C),3.55(m,2H,-NCO-NH-CH2-C),4.66(s,2H,O-CH2-C≡C),5.39(b,1H,NH-COO),7.05(s,1H,CH=N-CH=CH),7.49(b,1H,NH-CON),7.56(s,1H,CH=CH-N),8.25(s,1H,N-CH=N)。该反应的氯仿换成无活泼质子的其它有机溶剂如二氯甲烷,丙酮,四氢呋喃,DMF也同样进行并可得到类似的结果。(Allyl carbamate ethyl) dithioethyl 1-carbamide imidazole ((propargylcarbamate) ethyl disulfide ethyl 1-carbamide-imidazole, PPA-cyst-CI) synthesis: Weigh 1,1'-carbonyl di Dissolve 3.94 g of imidazole (CDI) in 40 ml of chloroform, drop 1.9 g of the above-mentioned PPA-cyst into the chloroform solution of CDI, react at room temperature for 4 hours, and the reaction solution changes from turbid to transparent. Water was added and washed three times, the organic phase was dried with anhydrous magnesium sulfate, filtered, and distilled under reduced pressure to obtain 1.9 g of white solid PPA-cyst-CI with a yield of 71%. 1 H-NMR in CDCl 3 : δ(ppm) 2.49(s, 1H, CH≡C), 2.78(t, 2H, S-CH 2 -CH 2 -NH-COO), 3.00(t, 2H, S- CH 2 -CH 2 -NH-CON), 3.50(m, 2H, -OCO-NH-CH 2 -C), 3.55(m, 2H, -NCO-NH-CH 2 -C), 4.66(s, 2H , O-CH 2 -C≡C), 5.39 (b, 1H, NH-COO), 7.05 (s, 1H, CH=N-CH=CH), 7.49 (b, 1H, NH-CON), 7.56 ( s, 1H, CH=CH-N), 8.25 (s, 1H, N-CH=N). The chloroform of this reaction is replaced with other organic solvents without active protons such as dichloromethane, acetone, tetrahydrofuran, and DMF is also carried out and similar results can be obtained.
实施例2单叠氮端基功能化的线形聚甲基丙烯酸-2-N,N-二甲氨基乙酯(mono-azide terminated poly(2-(dimethylamino)ethyl methacrylate),L-PDE-N3)的合成:Example 2 Mono-azide terminated poly(2-(dimethylamino)ethyl methacrylate), L-PDE-N 3 )Synthesis:
根据文献[X.L.Jiang,M.C.Lok,W.E.Hennink,Degradable-BrushedpHEMA-pDMAEMA synthesized via ATRP and click chemistry for gene delivery,Bioconjugate Chem.18(2007)2077-2084.]先合成引发剂2-溴-异丁酸-3-叠氮丙脂(BiBAP)。将6.29克单体甲基丙烯酸-2-N,N-二甲基氨乙酯,260毫克配体1,1,4,7,7,-五甲基二亚乙基三胺(PMDETA)和250毫克引发剂BiBAP溶解于15mL1,2-二氯代苯,在氮气下加入210mg溴化亚铜,然后通过三次真空-氮气循环除去体系中的氧气,混合液在50℃油浴中加热反应2小时。加入200毫升正己烷停止反应并沉淀出产物,然后反复沉淀2次进行纯化,并在真空干燥箱中干燥得到产物L-PDE-N3 5.22克,产率83%。通过核磁氢谱测得其数均分子量为8.6kDa,通过凝胶渗透色谱(GPC)联用多角度光散射检测器测得其重均分子量为12.7kDa,数均分子量为10.7kDa,多分散指数PDI为1.19,用L-PDE-N3-1表示。According to the literature [XLJiang, MCLok, WEHennink, Degradable-BrushedpHEMA-pDMAEMA synthesized via ATRP and click chemistry for gene delivery, Bioconjugate Chem.18(2007) 2077-2084.] first synthesize the initiator 2-bromo-isobutyric acid-3- Propylazide (BiBAP). 6.29 grams of monomer methacrylate-2-N, N-dimethylaminoethyl ester, 260 mg of
另一个L-PDE-N3的合成配方和步骤上,只是将反应混合液在55℃油浴中加热聚合反应2.5小时,沉淀纯化真空干燥得到L-PDE-N3 5.79克,产率92%,通过核磁氢谱测得其数均分子量为12.8kDa,通过GPC联用多角度光散射检测器测得其重均分子量为19.8kDa,数均分子量为18.5kDa,PDI为1.07,用L-PDE-N3-2表示。通过控制引发剂和单体的比例及反应条件,可以制得一系列分子量在2000-30000之间的不同的L-PDE-N3叠氮端基功能化的线形聚甲基丙烯酸二甲基氨乙酯。In another synthesis formula and steps of L-PDE-N 3 , the reaction mixture was heated and polymerized in an oil bath at 55°C for 2.5 hours, precipitated, purified and dried in vacuum to obtain 5.79 grams of L-PDE-N 3 with a yield of 92%. , the number average molecular weight measured by proton nuclear magnetic spectrum is 12.8kDa, the weight average molecular weight measured by GPC coupled with multi-angle light scattering detector is 19.8kDa, the number average molecular weight is 18.5kDa, and the PDI is 1.07. -N 3 -2 means. By controlling the ratio of initiator and monomer and the reaction conditions, a series of linear polydimethylammonium methacrylate functionalized with different L-PDE-N 3 azide end groups with a molecular weight of 2000-30000 can be prepared ethyl ester.
实施例3叠氮端基功能化的聚乙烯亚胺的合成The synthesis of the polyethylenimine of embodiment 3 azide end group functionalization
叠氮端基功能化的聚乙烯亚胺PEI800-(N3)1的合成(下标数字800表示PEI重均分子量为800,下标数字1表示每个聚乙烯亚胺的叠氮端基平均数约为1):参照文献[2008-033s Chem Comm,20071219,N2,190-192,Biodegradablemicrocapsules designed via‘click’chemistry,Bruno G.De Geest;Wim Van Camp,Filip E.Du Prez;Stefaan C.De Smedt;Jo Demeester;Wim E.Hennink]通过叠氮丙醇和1,1’-羰基二咪唑合成液体叠氮丙酯羰基咪唑(3-azidopropyl ester ofcarbonylimidazole,AP-CI)。将0.30克叠氮丙酯羰基咪唑(AP-CI)溶于60毫升氯仿,1.23克重均分子量为800的聚乙烯亚胺溶于20毫升氯仿,将它们在室温下混合反应2小时,再升温回流反应10小时,减压除去溶剂氯仿,得到含咪唑小分子的叠氮端基功能化的聚乙烯亚胺黄色液体1.2克。红外光谱分析表明该产物在2099cm-1处有明显的吸收峰,说明其含叠氮。核磁氢谱表明原料叠氮丙酯羰基咪唑已反应完全,并测得每个聚乙烯亚胺分子含1个叠氮基团。该反应的氯仿换成无活泼质子的其它有机溶剂如二氯甲烷,丙酮,四氢呋喃,DMF也同样进行,反应温度在30-80℃下搅拌反应2-48小时,并可得到类似的结果。Synthesis of polyethyleneimine PEI 800 -(N 3 ) 1 functionalized with azide end groups (the
叠氮端基功能化的聚乙烯亚胺PEI1800-(N3)1的合成(下标数字1800表示PEI重均分子量为1800,下标数字1表示每个聚乙烯亚胺的叠氮端基平均数约为1):将0.42克叠氮丙酯羰基咪唑溶于10毫升氯仿,4.0克重均分子量为1800的聚乙烯亚胺溶于40毫升氯仿,将它们在室温下混合反应2小时,升温回流10小时,减压除去溶剂氯仿,得到黄色油状粘稠液体4.4克,为含咪唑小分子的叠氮端基功能化的聚乙烯亚胺。红外光谱分析表明该产物在2099cm-1处有明显的吸收峰,说明其含叠氮。核磁氢谱表明原料叠氮丙酯羰基咪唑已反应完全,并测得平均每个聚乙烯亚胺分子平均含1个叠氮基团。该反应的氯仿换成无活泼质子的其它有机溶剂如二氯甲烷,丙酮,四氢呋喃,DMF也同样进行,反应温度在30-80℃下搅拌反应2-48小时,并可得到类似的结果。Synthesis of polyethyleneimine PEI 1800- (N 3 ) 1 functionalized with azide end groups (the subscript number 1800 indicates that the weight average molecular weight of PEI is 1800, and the
重均分子量在600-5000之间的聚乙烯亚胺PEI按摩尔比0.3-1.1∶1溶于有机溶剂中,在25-60℃下搅拌反应2-24小时,减压除去溶剂,得到含咪唑小分子的叠氮端基功能化的聚乙烯亚胺,其中的每个聚乙烯亚胺含叠氮端基的平均数量为0.3-1.1。Polyethyleneimine PEI with a weight average molecular weight between 600-5000 is dissolved in an organic solvent at a molar ratio of 0.3-1.1:1, stirred and reacted at 25-60°C for 2-24 hours, and the solvent is removed under reduced pressure to obtain imidazole-containing The azide end group functionalized polyethyleneimine of small molecules, wherein each polyethyleneimine has an average number of azide end groups of 0.3-1.1.
实施例4炔端基功能化的聚乙烯亚胺的合成The synthesis of the polyethylenimine of embodiment 4 alkyne end group functionalization
炔端基功能化的聚乙烯亚胺PEI800-(PPA-cyst)1的合成(下标数字800表示PEI重均分子量为800,下标数字1表示每个聚乙烯亚胺的炔端基平均数约为1):将实施例1制得的PPA-cyst-CI 1.26克溶于100毫升氯仿,3.07克重均分子量为800的聚乙烯亚胺溶于50毫升氯仿,将它们在室温下混合反应2小时,再升温回流反应24小时,减压除去溶剂氯仿,得到含咪唑小分子的炔端基功能化的聚乙烯亚胺PEI800-(PPA-cyst)1黄色粘稠液体4.26g,产率为98%。核磁氢谱表明原料PPA-cyst-CI已反应完全,并测得每个聚乙烯亚胺分子含1.0个炔基团。该反应的氯仿换成无活泼质子的其它有机溶剂如二氯甲烷,丙酮,四氢呋喃,DMF也同样进行,反应温度在30-80℃下搅拌反应2-48小时。Synthesis of polyethyleneimine PEI 800- (PPA-cyst) 1 functionalized with alkyne end groups (the
炔端基功能化的聚乙烯亚胺PEI1800-(PPA-cyst)1的合成(下标数字1800表示PEI重均分子量为1800,下标数字1表示每个聚乙烯亚胺的炔端基平均数约为1):与上述合成PEI800-(PPA-cyst)1相同,将实施例1制得的PPA-cyst-CI 0.50克溶于50毫升氯仿,2.74克重均分子量为1800的聚乙烯亚胺溶于50毫升氯仿,将它们在室温下混合反应2小时,再升温回流反应24小时,减压除去溶剂氯仿,得到含咪唑小分子的炔端基功能化的聚乙烯亚胺PEI1800-(PPA-cyst)1黄色粘稠液体2.96g。核磁氢谱表明原料PPA-cyst-CI已反应完全,并测得每个聚乙烯亚胺分子含1.0个炔基团。该反应的氯仿换成无活泼质子的其它有机溶剂如二氯甲烷,丙酮,四氢呋喃,DMF也同样进行,反应温度在30-80℃下搅拌反应2-48小时。Synthesis of polyethyleneimine PEI1 800 -(PPA-cyst) 1 functionalized with alkyne end group (subscript number 1800 indicates PEI weight average molecular weight is 1800,
单炔端基功能化的聚乙烯亚胺PEI1800-(PPA-cyst)的合成(下标数字1800表示PEI重均分子量为1800):与上述合成PEI1800-(PPA-cyst)1相同,将实施例1制得的PPA-cyst-CI 0.33克溶于30毫升氯仿,5.40克重均分子量为1800的聚乙烯亚胺溶于80毫升氯仿,将它们在室温下混合反应1小时,再升温回流反应24小时,减压除去溶剂氯仿,得到含咪唑小分子的单炔端基功能化的聚乙烯亚胺PEI1800-(PPA-cyst)黄色粘稠液体5.61g。核磁氢谱(图1)表明原料PPA-cyst-CI已反应完全,并测得每个聚乙烯亚胺分子平均含0.33个炔基团,确保绝大多数的每个聚乙烯亚胺含炔端基为1个或者0个。该反应的氯仿换成无活泼质子的其它有机溶剂如二氯甲烷,丙酮,四氢呋喃,DMF也同样进行,反应温度在30-80℃下搅拌反应2-48小时。重均分子量在600-5000之间的聚乙烯亚胺PEI均可以用上述方法改性制得炔端基功能化的聚乙烯亚胺PEI,其中的每个聚乙烯亚胺含炔端基的平均数量为0.3-1.1。Synthesis of polyethyleneimine PEI 1800- (PPA-cyst) functionalized by mono-alkyne end group (subscript number 1800 represents PEI weight-average molecular weight is 1800): same as above-mentioned synthetic PEI 1800- (PPA-cyst) 1 , will 0.33 grams of PPA-cyst-CI prepared in Example 1 was dissolved in 30 milliliters of chloroform, and 5.40 grams of polyethyleneimine with a weight average molecular weight of 1800 was dissolved in 80 milliliters of chloroform, and they were mixed and reacted at room temperature for 1 hour, and then heated to reflux After reacting for 24 hours, the solvent chloroform was removed under reduced pressure to obtain 5.61 g of a yellow viscous liquid of polyethyleneimine PEI 1800 -(PPA-cyst) functionalized with a monoalkyne end group containing a small imidazole molecule. The proton nuclear magnetic spectrum (Figure 1) shows that the raw material PPA-cyst-CI has reacted completely, and it is measured that each polyethyleneimine molecule contains an average of 0.33 alkyne groups, ensuring that most of each polyethyleneimine contains an alkyne end The base is 1 or 0. The chloroform of this reaction is replaced by other organic solvents without active protons such as dichloromethane, acetone, tetrahydrofuran, DMF, and the same is carried out, and the reaction temperature is 30-80 ° C and the reaction is stirred for 2-48 hours. Polyethyleneimine PEI with a weight-average molecular weight between 600-5000 can be modified by the above method to obtain alkyne-end functionalized polyethyleneimine PEI, wherein each polyethyleneimine contains an average of alkyne-end groups The quantity is 0.3-1.1.
实施例5侧链含双硫键和炔基基团的聚天冬氨基酸衍生物P(Asp-ss-Al)的制备方法:Example 5 The preparation method of the polyaspartic acid derivative P(Asp-ss-Al) containing a disulfide bond and an alkynyl group in the side chain:
将自制的聚琥珀酰亚胺(PSI)0.375克溶解于12毫升DMF中,再将实施例1制得的(烯丙基氨基甲酸酯乙基)二硫乙胺化合物(PPA-cyst)1.36克加入DMF溶液中,于55℃反应24小时。分别用200毫升乙醚沉淀纯化三次,真空干燥得到黄色粉末固体0.92克。红外光谱分析表明该产物在2121cm-1处有明显的吸收峰,说明其含有炔基。产物核磁氢谱在4.0-4.8ppm出现新的特征峰,并计算出聚琥珀酰亚胺的开环率为65%,该产物用P(Asp-ss-Al)-1表示。Dissolve 0.375 grams of self-made polysuccinimide (PSI) in 12 milliliters of DMF, then (allyl carbamate ethyl) dithioethylamine compound (PPA-cyst) 1.36 g into the DMF solution and reacted at 55°C for 24 hours. Precipitate and purify three times with 200 ml of diethyl ether, and dry in vacuo to obtain 0.92 g of a yellow powder solid. Infrared spectrum analysis showed that the product had an obvious absorption peak at 2121cm-1, indicating that it contained an alkynyl group. A new characteristic peak appears at 4.0-4.8ppm in the proton nuclear magnetic spectrum of the product, and the calculated ring-opening rate of polysuccinimide is 65%. The product is represented by P(Asp-ss-Al)-1.
侧链含100%炔基基团的聚天冬氨基酸衍生物P(Asp-ss-Al)的制备:实验步骤同上,称取PSI 1.0克溶解于20毫升DMF中,再将实施例1制得的(烯丙基氨基甲酸酯乙基)二硫乙胺化合物(PPA-cyst)4.56克加入DMF溶液中,65℃反应48小时。用300毫升乙醚沉淀纯化三次,真空干燥得到黄色粉末固体1.74克。红外光谱分析表明该产物在2121cm-1处有明显的吸收峰,说明其含有炔基。核磁氢谱表明聚琥珀酰亚胺在5.0-5.2的特征峰消失,聚琥珀酰亚胺的开环率为100%,该产物用P(Asp-ss-Al)-2表示。The preparation of the polyaspartic acid derivative P (Asp-ss-Al) that side chain contains 100% alkynyl group: Experimental procedure is the same as above, weighs 1.0 grams of PSI and dissolves in 20 milliliters of DMF, then the preparation of Example 1 4.56 g of (allyl carbamate ethyl) dithioethylamine compound (PPA-cyst) was added into the DMF solution, and reacted at 65° C. for 48 hours. It was purified by precipitation three times with 300 ml of diethyl ether, and dried in vacuo to obtain 1.74 g of a yellow powder solid. Infrared spectrum analysis showed that the product had an obvious absorption peak at 2121cm-1, indicating that it contained an alkynyl group. The proton nuclear magnetic spectrum shows that the characteristic peak of polysuccinimide at 5.0-5.2 disappears, and the ring-opening rate of polysuccinimide is 100%. The product is represented by P(Asp-ss-Al)-2.
可以根据PPA-cyst和PSI的摩尔比在0.2-2∶1,在20-70℃下搅拌反应2-48小时,制得侧链含炔基基团摩尔百分比在15%-100%的聚天冬氨基酸衍生物P(Asp-ss-Al)According to the molar ratio of PPA-cyst and PSI at 0.2-2:1, stirring and reacting at 20-70°C for 2-48 hours, the polyhexine with a molar percentage of alkynyl groups in the side chain of 15%-100% can be prepared. Aspartic Amino Acid Derivative P(Asp-ss-Al)
实施例6侧链含叠氮基团的聚天冬氨基酸衍生物的制备方法:Example 6 The preparation method of polyaspartic acid derivatives containing azide groups in the side chain:
将自制的聚琥珀酰亚胺(PSI)0.28克和自制的2-叠氮乙胺0.1,0.2或者0.5克(分别按叠氮与PSI重复单元的摩尔比0.4∶1,0.8∶1和2∶1)加入溶剂中,在室温下混合反应96小时,再沉淀纯化制得侧链含不同比例的叠氮基团的聚天冬氨基酸衍生物P(Asp-Az),产物分别为0.29克,0.30克,或者0.33克。后者经核磁氢谱检测其PSI环已全部开环,说明所有侧链已接上叠氮基团。前两者的产物经核磁氢谱检测其还有未开环的结构存在,再加入过量的乙醇胺开环反应24小时,制得侧链含叠氮基团和乙醇基团的聚天冬氨基酸衍生物P(Asp-Az),经核磁氢谱检测其侧链中含叠氮基团的百分比分别为33%和65%(图1),分别用简式P(Asp-Az)0.33(Asp-EA)0.67和P(Asp-Az)0.65(Asp-EA)0.35表示。红外光谱分析表明该类产物在2100cm-1处有明显的吸收峰,说明其含叠氮。加入过量的乙醇胺开环也可用N,N-二甲基丙二胺或者N,N-二甲基乙二胺,或者丙醇胺、丁醇胺或者戊醇胺代替,合成制得侧链含不同比例的叠氮基团的聚天冬氨基酸衍生物P(Asp-Az),该反应可在20-70℃下搅拌反应2-200小时。0.28 grams of self-made polysuccinimide (PSI) and 0.1, 0.2 or 0.5 grams of self-made 2-azidoethylamine (according to the molar ratio of azide and PSI repeating unit respectively 0.4:1, 0.8:1 and 2: 1) Add in the solvent, mix and react at room temperature for 96 hours, reprecipitate and purify to obtain polyaspartic acid derivatives P(Asp-Az) with different proportions of azide groups in the side chain, and the products are 0.29 grams, 0.30 grams, or 0.33 grams. The PSI rings of the latter have been completely opened as detected by proton nuclear magnetic spectroscopy, indicating that all side chains have been connected with azide groups. The products of the former two were detected by proton nuclear magnetic spectrum, and there were unopened ring structures, and then an excessive amount of ethanolamine was added for ring-opening reaction for 24 hours to obtain polyaspartic acid derivatives containing azide groups and ethanol groups in the side chains. P(Asp-Az), the percentages of azide-containing groups in its side chain detected by proton nuclear magnetic spectrum are 33% and 65% respectively (Fig. 1). EA) 0.67 and P(Asp-Az) 0.65 (Asp-EA) 0.35 . Infrared spectrum analysis shows that this kind of product has obvious absorption peak at 2100cm -1 , indicating that it contains azide. Adding excessive ethanolamine to open the ring can also be replaced by N,N-dimethylpropylenediamine or N,N-dimethylethylenediamine, or propanolamine, butanolamine or pentanolamine, and the side chain containing For the polyaspartic acid derivative P(Asp-Az) with different ratios of azide groups, the reaction can be stirred at 20-70°C for 2-200 hours.
实施例7侧链含双硫键和炔基基团的聚甲基丙烯酰胺或者聚丙烯酰胺类衍生物的制备方法:Example 7 The preparation method of polymethacrylamide or polyacrylamide derivatives containing disulfide bonds and alkynyl groups in the side chain:
侧链含双硫键和炔基基团的甲基丙烯酰胺类单体PPA-cyst-MAm的合成:将实施例1制得的(烯丙基氨基甲酸酯乙基)二硫乙胺化合物(PPA-cyst)2.5克,三乙胺1.62克溶解在40毫升干燥二氯甲烷中,用冰水浴冷却,逐滴加入1.67克甲基丙烯酰氯的二氯甲烷(20毫升)溶液,在冰水浴中反应2小时,再在室温反应15小时,纯化重结晶得到白色晶体PPA-cyst-MAm,产率为46%.1H-NMR inCDCl3:δ(ppm)1.98(s,3H,≡C-CH2-O),2.47(s,1H,CH≡C),2.83(m,4H,S-CH2-C),3.52(q,2H,NH-CH2-C),3.66(q,2H,O-CO-NH-CH2-C),4.68(s,2H,O-CH2-C≡C),5.36 & 5.74(2H,CH2=C).The synthesis of the methacrylamide monomer PPA-cyst-MAm that side chain contains disulfide bond and alkynyl group: the (allyl carbamate ethyl) dithioethylamine compound that
称取单体PPA-cyst-MAm 0.907克,引发剂偶氮二异丁腈(AIBN)9.85毫克溶解于4毫升干燥的DMF中,通过两次真空-氮气循环除去体系中的氧气,并在氮气保护下在70℃油浴反应24小时。分别用200毫升乙醚沉淀纯化三次得到白色粉末0.68克。通过凝胶渗透色谱(GPC)联用多角度光散射检测器测得其重均分子量为15.1kDa,多分散指数PDI为1.98。红外光谱分析表明该产物在2127cm-1处有明显的吸收峰,说明其含有炔基。Weigh 0.907 grams of monomer PPA-cyst-MAm, 9.85 milligrams of initiator azobisisobutyronitrile (AIBN) are dissolved in 4 milliliters of dry DMF, remove the oxygen in the system by two vacuum-nitrogen cycles, and React in an oil bath at 70°C for 24 hours under protection. Precipitate and purify three times with 200 ml of diethyl ether respectively to obtain 0.68 g of white powder. The weight-average molecular weight measured by gel permeation chromatography (GPC) coupled with a multi-angle light scattering detector is 15.1 kDa, and the polydispersity index PDI is 1.98. Infrared spectrum analysis showed that the product had an obvious absorption peak at 2127cm-1, indicating that it contained an alkynyl group.
制备上述单体时用丙烯酰氯代替甲基丙烯酰氯反应,再聚合反应则同样制得聚丙烯酰胺类衍生物P(PPA-cyst-Am)。聚合反应时加入引发剂如偶氮二异丁腈AIBN和溶剂,在50-80℃下搅拌反应2-24小时,或者通过ATRP聚合也可制得侧链含双硫键和炔基基团的聚甲基丙烯酰胺类衍生物P(PPA-cyst-Mam)或者聚丙烯酰胺类衍生物P(PPA-cyst-Am)When preparing the above-mentioned monomers, acryloyl chloride is used instead of methacryloyl chloride for reaction, and then polyacrylamide derivative P(PPA-cyst-Am) is also obtained in the repolymerization reaction. Add an initiator such as azobisisobutyronitrile AIBN and a solvent during the polymerization reaction, and stir the reaction at 50-80°C for 2-24 hours, or it can also be prepared by ATRP polymerization containing disulfide bonds and alkynyl groups in the side chain. Polymethacrylamide derivative P(PPA-cyst-Mam) or polyacrylamide derivative P(PPA-cyst-Am)
实施例8-11均为点击化学合成含双硫键改性的还原敏感性梳型高分子阳离子聚合物系列Examples 8-11 are click chemical synthesis of reduction-sensitive comb-type high molecular weight cationic polymer series containing disulfide bond modification
实施例8含双硫键改性梳型高分子量聚阳离子P(Asp-ss-Al-Az-PDE)的制备:
点击化学合成含双硫键的梳形聚甲基丙烯酸二甲基氨乙酯P(Asp-ss-Al-Az-PDE)-1:将实施例2制得的单叠氮端基功能化的线形聚甲基丙烯酸-2-N,N-二甲氨基乙酯L-PDE-N3-1 200毫克,实施例5中制得的侧链含炔基基团摩尔百分比为65%的聚天冬氨基酸衍生物P(Asp-ss-Al)-130毫克溶解在10毫升DMF中,在氮气下加入溴化亚铜15毫克,并在氮气保护下,在50℃油浴中反应2天,装入透析袋(MWCO 8k-12kDa)用水透析,冷冻干燥得到梳形聚甲基丙烯酸二甲基氨乙酯阳离子聚合物P(Asp-ss-Al-Az-PDE)-1,其核磁氢谱在8.15ppm出现新的特征峰,为点击化学生成三唑环上的质子特征峰。红外光谱在2100cm-1附近没有明显的吸收峰,表明炔基和叠氮基团在点击化学反应之后基本消失,说明点击化学已基本完成。通过凝胶渗透色谱(GPC)联用多角度光散射检测器测得其重均分子量为243kDa,PDI为1.63。Click chemistry synthesis of comb-shaped polydimethylaminoethyl methacrylate P(Asp-ss-Al-Az-PDE)-1 containing disulfide bonds: functionalized monoazide end group prepared in Example 2 Linear polymethacrylic acid-2-N, N-dimethylaminoethyl ester L-PDE-N 3 -1 200 milligrams, the side chain containing alkynyl group mole percentage that makes in the
另一个含双硫键的梳形聚甲基丙烯酸二甲基氨乙酯P(Asp-ss-Al-Az-PDE)-2的合成:步骤同上,区别在于L-PDE-N3-1的用量减少到102毫克,制得的梳形聚甲基丙烯酸二甲基氨乙酯阳离子聚合物用P(Asp-ss-Al-Az-PDE)-2表示,其重均分子量为157kDa,PDI为1.80。使用溶剂DMSO代替DMF,该点击化学反应也可以进行。该反应中的CuBr可改用CuCl;该反应也可以不使用CuBr,而采用提高反应温度(80℃)和延长反应时间(48小时)。Synthesis of another comb-shaped polydimethylaminoethyl methacrylate P(Asp-ss-Al-Az-PDE)-2 containing a disulfide bond: the steps are the same as above, the difference is that L-PDE-N 3 -1 Consumption is reduced to 102 milligrams, and the prepared comb-shaped polydimethylaminoethyl methacrylate cationic polymer is represented by P(Asp-ss-Al-Az-PDE)-2, and its weight-average molecular weight is 157kDa, and PDI is 1.80. This click chemistry reaction can also be performed using the solvent DMSO instead of DMF. CuBr in this reaction can be replaced by CuCl; this reaction can also not use CuBr, but adopts raising reaction temperature (80 ℃) and prolonging reaction time (48 hours).
实施例9含双硫键改性的梳型高分子量阳离子聚合物P(Asp-ss-Al-Az-PEI)的制备:将实施例5制得的侧链含双硫键和炔基基团的聚天冬氨基酸衍生物P(Asp-ss-Al)-181毫克,N,N-二甲基丙二胺40毫克溶解于10毫升DMF中,常温反应12小时,然后加入实施例3中制得的叠氮端基功能化的聚乙烯亚胺PEI1800-(N3)1 1.07克,通过三次真空-氮气循环除去体系中的氧气,在氮气下加入溴化亚铜18毫克,并在氮气保护下在50℃油浴中反应2天,装入透析袋(MSCO3.5kDa)用水透析,过滤透析中出现的沉淀,冷冻干燥得到P(Asp-ss-Al-Az-PEI)70毫克。这里的N,N-二甲基丙二胺也可用过量的N,N-二甲基乙二胺,乙醇胺、丙醇胺、丁醇胺或者戊醇胺代替。Example 9 Preparation of comb-shaped high molecular weight cationic polymer P(Asp-ss-Al-Az-PEI) containing disulfide bond modification: the side chain prepared in Example 5 contains disulfide bond and alkynyl group The polyaspartic acid derivative P(Asp-ss-Al)-181 mg, 40 mg of N,N-dimethylpropylenediamine were dissolved in 10 milliliters of DMF, reacted at room temperature for 12 hours, and then added the preparation in Example 3 The polyethyleneimine PEI 1800- (N 3 ) 1 1.07 grams of the obtained azide end group functionalization, removes the oxygen in the system by three vacuum-nitrogen circulations, adds
实施例10含双硫键改性的梳型高分子量阳离子聚合物P(PPA-cyst-MAm-PDE)的制备:
称取实施例7制得的P(PPA-cyst-MAm)20毫克,实施例2制得的L-PDE-N3-2216或325毫克,溶解在10毫升DMF中,通过三次真空-氮气循环除去体系中的氧气,在氮气下加入溴化亚铜15毫克,并在氮气保护下在50℃油浴中反应2天。制得的聚合物溶解装入透析袋(MWCO 8k-12kDa)用水透析,冷冻干燥分别得到梳形聚甲基丙烯酸二甲基氨乙酯阳离子聚合物191毫克(用P(PPA-cyst-MAm-PDE)-1表示)和305毫克(用P(PPA-cyst-MAm-PDE)-2表示),通过GPC联用多角度光散射检测器测得P(PPA-cyst-MAm-PDE)-1重均分子量为266kDa,PDI为1.24,接上的支链数约月为13条;P(PPA-cyst-MAm-PDE)-2的重均分子量88.5kDa,PDI为1.60,接上的支链数约为4条。Weigh 20 mg of P(PPA-cyst-MAm) prepared in Example 7, L-PDE-N 3 -2216 or 325 mg obtained in Example 2, dissolve in 10 ml of DMF, and pass through three vacuum-nitrogen cycles The oxygen in the system was removed, and 15 mg of cuprous bromide was added under nitrogen, and reacted in an oil bath at 50°C for 2 days under the protection of nitrogen. The prepared polymer is dissolved and loaded into a dialysis bag (MWCO 8k-12kDa) for water dialysis, and freeze-dried to obtain 191 mg of comb-shaped polydimethylaminoethyl methacrylate cationic polymer (using P(PPA-cyst-MAm- PDE)-1) and 305 mg (expressed as P(PPA-cyst-MAm-PDE)-2), P(PPA-cyst-MAm-PDE)-1 was measured by GPC with a multi-angle light scattering detector The weight average molecular weight is 266kDa, the PDI is 1.24, and the number of connected branched chains is about 13; the weight average molecular weight of P(PPA-cyst-MAm-PDE)-2 is 88.5kDa, the PDI is 1.60, and the connected branched chains The number is about 4.
实施例11含双硫键改性的梳型高分子量聚阳离子P(Asp-Az-Al-ss-PEI)的制备:
将实施例6中制得的P(Asp-Az)0.33(Asp-EA)0.67 50毫克,和实施例4中制得的单炔端基功能化的聚乙烯亚胺PEI-(PPA-cyst)1.18克(每个聚乙烯亚胺分子平均含0.33个炔基团,按炔基端基与叠氮的摩尔比2∶1),溶解于5毫升水和5毫升DMF的混合溶剂中,加入CuBr 20毫克,在氮气保护下,在50℃油浴中反应2天。制得的聚合物溶液装入透析袋(MWCO 3.5kDa)用水透析5天,冷冻干燥得含双硫键改性的梳型高分子量阳离子聚合物P(Asp-Az-Al-ss-PEI)(Asp-EA)0.67。其核磁氢谱在7.9ppm处有明显的峰为三唑环的H,说明通过点击化学生成了三唑环,红外光谱分析表明该产物在2100cm-1处没有明显的吸收峰,说明叠氮侧基基本反应。使用溶剂DMSO代替DMF,该点击化学反应也可以进行。该反应中的CuBr可改用CuCl;该反应也可以不使用CuBr,而采用提高反应温度(80℃)和延长反应时间(48小时)。The P(Asp-Az) 0.33 (Asp-EA) 0.67 50 mg prepared in Example 6, and the polyethyleneimine PEI-(PPA-cyst) of the mono-alkyne terminal functionalization prepared in Example 4 1.18 g (each polyethyleneimine molecule contains an average of 0.33 alkyne groups, according to the molar ratio of alkynyl end group to azide 2:1), dissolved in a mixed solvent of 5 ml water and 5 ml DMF, added
将实施例6中制得的P(Asp-Az)0.65(Asp-EA)0.35 50毫克,和实施例4中制得的单炔端基功能化的聚乙烯亚胺PEI-(PPA-cyst)2.41克(每个聚乙烯亚胺分子平均含0.33个炔基团,按炔基端基与叠氮的摩尔比2∶1),溶解于5毫升水和5毫升DMF的混合溶剂中,加入CuBr 20毫克,在氮气保护下,在50℃油浴中反应2天。制得的聚合物溶液装入透析袋(MWCO 3.5kDa)用水透析,冷冻干燥得含双硫键改性的梳型高分子量阳离子聚合物P(Asp-Az-Al-ss-PEI)(Asp-EA)0.35。其核磁氢谱(图1)在7.9ppm处有明显的峰为三唑环的H,说明通过点击化学生成了三唑环。使用溶剂DMSO代替DMF,该点击化学反应也可以进行。该反应中的CuBr可改用CuCl;该反应也可以不使用CuBr,而采用提高反应温度(80℃)和延长反应时间(48小时)。The P(Asp-Az) 0.65 (Asp-EA) 0.35 50 mg prepared in Example 6, and the polyethyleneimine PEI-(PPA-cyst) of the monoalkyne terminal functionalization prepared in Example 4 2.41 g (each polyethylenimine molecule contains an average of 0.33 alkyne groups, according to the molar ratio of alkynyl end group to azide 2:1), dissolved in a mixed solvent of 5 ml water and 5 ml DMF, added
将实施例6中制得的P(Asp-Az)50毫克,和实施例4中制得的单炔端基功能化的聚乙烯亚胺PEI-(PPA-cyst)2.62克(每个聚乙烯亚胺分子平均含0.33个炔基团,按炔基端基与叠氮的摩尔比2∶1),溶解于10毫升DMF中,加入CuBr20毫克,在氮气保护下,在50℃油浴中反应2天。制得的聚合物溶液装入透析袋(MWCO 3.5kDa)用水透析,冷冻干燥得含双硫键改性的梳型高分子量阳离子聚合物P(Asp-Az-Al-ss-PEI)其核磁氢谱在7.9ppm处有明显的峰为三唑环的H,说明通过点击化学生成了三唑环,通过凝胶渗透色谱(GPC)测得其流出时间大大先于原料PEI-1.8kDa的出峰时间,说明含双硫键改性的梳型高分子量阳离子聚合物P(Asp-Az-Al-ss-PEI)的分子量为远大于原料PEI-1.8kDa的分子量。使用溶剂DMSO代替DMF,该点击化学反应也可以进行。该反应中的CuBr可改用CuCl;该反应也可以不使用CuBr,而采用提高反应温度(80℃)和延长反应时间(48小时)。50 milligrams of P(Asp-Az) made in embodiment 6, and 2.62 grams of polyethyleneimine PEI-(PPA-cyst) of mono-alkyne terminal functionalization made in embodiment 4 (each polyethylene The imine molecule contains an average of 0.33 alkyne groups, according to the molar ratio of alkyne end group to azide (2:1), dissolve in 10 ml of DMF, add 20 mg of CuBr, and react in an oil bath at 50°C under
实施例12含双硫键改性的梳型高分子量阳离子聚合物的还原敏感特性Example 12 Reduction Sensitive Properties of Comb-type High Molecular Weight Cationic Polymers Containing Disulfide Bond Modification
将实施例10制得的P(PPA-cyst-MAm-PDE)-1溶解在0.3mol/L NaAc,pH 4.4的缓冲溶液配置为5.0mg/mL的溶液。取1mL该聚合物溶液,加入53微升1.0mol/L的1,4-二硫苏糖醇(DTT)水溶液混合,常温下放置1小时,用GPC联用多角度光散射检测器测得其重均分子量为24.4kDa,PDI为1.11,见图2,这说明降解产物的分子量与所用原料L-PDE-N3-2的分子量(Mw 19.8kDa,PDI 1.07)较接近,说明该含双硫键的改性梳型高分子量阳离子聚合物具有还原敏感特性。The P(PPA-cyst-MAm-PDE)-1 prepared in Example 10 was dissolved in 0.3 mol/L NaAc, pH 4.4 buffer solution to prepare a 5.0 mg/mL solution. Take 1mL of this polymer solution, add 53 microliters of 1.0mol/
分别将P(PPA-cyst-MAm-PDE)-1和P(PPA-cyst-MAm-PDE)-2溶解在HBS缓冲液(20mM Hepes,130mM NaCl,pH 7.4)配置为62.5毫克/L溶液,取600微升聚合物溶液加入到150微升pcDNA3-Luc plasmid质粒DNA溶液中(50毫克/L in HBS),混合均匀并在37℃下复合30分钟,然后加入8.3微升1.0mol/L的1,4-二硫苏糖醇(DTT)水溶液,然后用动态光散射检测溶液中粒子粒径随时间的改变,结果见图3。由该图可知没有加入DTT复合粒子稳定,而加入DTT后复合粒子迅速增大不稳定,这也说明该类含双硫键的改性梳型高分子量阳离子聚合物具有还原敏感特性。Dissolve P(PPA-cyst-MAm-PDE)-1 and P(PPA-cyst-MAm-PDE)-2 in HBS buffer (20mM Hepes, 130mM NaCl, pH 7.4) respectively to configure 62.5mg/L solution, Add 600 microliters of polymer solution to 150 microliters of pcDNA3-Luc plasmid DNA solution (50 mg/L in HBS), mix well and compound at 37°C for 30 minutes, then add 8.3 microliters of 1.0mol/
实施例13阳离子聚合物体外细胞毒性Example 13 Cationic polymer cytotoxicity in vitro
阳离子高分子对细胞的毒性是高分子基因传递载体的一个重要评价指标,一般测试在不同浓度聚合物作用下对细胞的抑制率来衡量。这里将实施例8-11中合成的含双硫键改性的梳型高分子量阳离子聚合物对293T细胞的体外细胞毒性通过四甲基偶氮唑盐(MTT)比色法来测量。The toxicity of cationic polymers to cells is an important evaluation index of polymer gene delivery carriers, which is generally measured by the inhibition rate of cells under the action of different concentrations of polymers. Here, the in vitro cytotoxicity of the disulfide bond-modified comb-shaped high-molecular-weight cationic polymers synthesized in Examples 8-11 on 293T cells was measured by a tetramethylazolium salt (MTT) colorimetric method.
293T细胞在96孔培养板中以3000细胞/孔接种并加入100μL含血清的DMEM培养基,在5%CO2培养箱中于37℃培养48小时。向每孔细胞中分别加入过滤灭菌的不同浓度的聚合物溶液(0.01 to 0.20mg/mL)100μL和100μL新鲜DMEM培养基)。继续培养48h至材料作用期结束,去除所有含有细胞的孔中的培养基,加入200μL新鲜的DMEM培养基。所有孔中各加入20μL MTT(5mg/ml)。用铝箔包裹培养板,于37℃湿润环境中温育4h。弃去孔中的培养基和MTT,各加入200μL DMSO其中并在室温下振荡,用酶标仪(550 BIO-RAD,美国)在570nm处记录吸光值。根据吸光值计算细胞相对成活率。293T cells were seeded at 3000 cells/well in a 96-well culture plate and added with 100 μL of serum-containing DMEM medium, and cultured at 37°C for 48 hours in a 5% CO2 incubator. Add filter-sterilized polymer solutions of different concentrations (0.01 to 0.20 mg/mL) (100 μL and 100 μL fresh DMEM medium) to each well of cells, respectively. Continue culturing for 48 h until the end of the material action period, remove the medium in all wells containing cells, and add 200 μL of fresh DMEM medium. 20 μL of MTT (5 mg/ml) was added to all wells. Wrap the culture plate with aluminum foil and incubate for 4 h at 37°C in a humid environment. The culture medium and MTT in the wells were discarded, 200 μL of DMSO was added to each well and shaken at room temperature, and the absorbance value was recorded at 570 nm with a microplate reader (550 BIO-RAD, USA). The relative cell survival rate was calculated according to the absorbance value.
实施例11中制备的含双硫键改性的梳型高分子量阳离子聚合物P(Asp-Az-Al-ss-PEI)(Asp-EA)0.67,P(Asp-Az-Al-ss-PEI)(Asp-EA)0.35和P(Asp-Az-Al-ss-PEI)及对照聚合物PEI 25kDa的毒性见图4,该图说明当聚合物的浓度低于0.03毫克/毫升,加入双硫键改性的梳型高分子量阳离子聚合物P(Asp-Az-Al-ss-PEI)(Asp-EA)0.67,P(Asp-Az-Al-ss-PEI)(Asp-EA)0.35和P(Asp-Az-Al-ss-PEI)时相对细胞存活率在80%左右,而加入0.03毫克/毫升25kDaPEI时相对细胞存活率小于20%。The comb-shaped high molecular weight cationic polymer P(Asp-Az-Al-ss-PEI)(Asp-EA) prepared in Example 11 containing disulfide bond modification 0.67 , P(Asp-Az-Al-ss-PEI )(Asp-EA) 0.35 and P(Asp-Az-Al-ss-PEI) and the toxicity of the control polymer PEI 25kDa are shown in Figure 4, which shows that when the concentration of the polymer is lower than 0.03 mg/ml, adding disulfide Bond-modified comb-type high molecular weight cationic polymer P(Asp-Az-Al-ss-PEI)(Asp-EA) 0.67 , P(Asp-Az-Al-ss-PEI)(Asp-EA) 0.35 and P (Asp-Az-Al-ss-PEI) relative cell viability was about 80%, while relative cell viability was less than 20% when 0.03 mg/ml 25kDa PEI was added.
实施例8中制备的含双硫键改性梳型高分子量聚阳离子P(Asp-ss-Al-Az-PDE)-1和P(Asp-ss-Al-Az-PDE)-2及对照聚合物PEI 25kDa的毒性见图5,制备P(Asp-ss-Al-Az-PDE)-1和P(Asp-ss-Al-Az-PDE)-2的原料低分子量聚合物L-PDE-N3-1及由普通自由基聚合合成的线形高分子量的PDE(HMPDE,重均分子量154kDa,PDI 1.58.4)的毒性作为对照也见图5。该图说明当聚合物的浓度低于0.03毫克/毫升,加入双硫键改性的梳型高分子量阳离子聚合物P(Asp-ss-Al-Az-PDE)-1和P(Asp-ss-Al-Az-PDE)-2时相对细胞存活率大于90%,而加入0.03毫克/毫升25kDa PEI时相对细胞存活率小于10%。,原料低分子量聚合物L-PDE-N3-1的毒性很低,但P(Asp-ss-Al-Az-PDE)-2的毒性比与其分子量相当的线形高分子量HMPDE的毒性要低得多。这表明含双硫键改性的梳型高分子量阳离子聚合物的毒性较低。The disulfide bond-containing modified comb-type high molecular weight polycation P(Asp-ss-Al-Az-PDE)-1 and P(Asp-ss-Al-Az-PDE)-2 prepared in Example 8 and the control polymerization The toxicity of substance PEI 25kDa is shown in Fig. 5, the raw material low molecular weight polymer L-PDE-N of preparation P(Asp-ss-Al-Az-PDE)-1 and P(Asp-ss-Al-Az-PDE)-2 The toxicity of 3-1 and linear high molecular weight PDE (HMPDE, weight average molecular weight 154kDa, PDI 1.58.4) synthesized by ordinary free radical polymerization is also shown in Fig. 5 as a control. The figure shows that when the concentration of the polymer is lower than 0.03 mg/ml, the addition of the disulfide bond-modified comb-shaped high molecular weight cationic polymers P(Asp-ss-Al-Az-PDE)-1 and P(Asp-ss- The relative cell survival rate was greater than 90% when Al-Az-PDE)-2 was added, while the relative cell survival rate was less than 10% when 0.03 mg/ml 25kDa PEI was added. , the toxicity of the raw material low molecular weight polymer L-PDE-N 3 -1 is very low, but the toxicity of P(Asp-ss-Al-Az-PDE)-2 is much lower than that of linear high molecular weight HMPDE with comparable molecular weight many. This indicates that the comb-type high molecular weight cationic polymers modified with disulfide bonds are less toxic.
实施例14聚合物/DNA复合物在无血清存在时的体外转染效率The in vitro transfection efficiency of
将实施例8-11中制得的含双硫键改性的梳型高分子量阳离子聚合物分别溶于NaCl溶液(150mmol/L,pH7.4),过滤灭菌,制备成相应浓度的溶液,在1.5mL无菌离心管中加入50μL含1.0μg质粒DNA(pcDNA3-Luc是荧光素酶的报告基因)溶液,按照N/P比为10-50加入相应量的50μL阳离子聚合物溶液,与DNA复合,震荡5s,该复合物在37℃静置半小时后用于细胞转染实验。用25kDa的PEI和1.8kDa的PEI作为对照,比较了复合物对293T和HeLa细胞的体外转染效率(加入复合物和无血清DMEM培养基后在37℃转染4h,培养基换成1mL完全DMEM培养基后在37℃继续培养48h)。图6展示了含双硫键改性的梳型高分子量阳离子聚合物P(Asp-Az-Al-ss-PEI)(Asp-EA)0.67,P(Asp-Az-Al-ss-PEI)(Asp-EA)0.35和P(Asp-Az-Al-ss-PEI)在不同的聚合物/DNA质量比时对293T细胞的体外荧光素酶的转染表达效率。其中P(Asp-Az-Al-ss-PEI)(Asp-EA)0.67的复合物的基因转染效率高于常用高分子基因载体参照聚合物25kDa PEI的复合物基因转染效率。图7展示了P(Asp-ss-Al-Az-PDE)-1和P(Asp-ss-Al-Az-PDE)-2,低分子量聚合物L-PDE-N3-1和线形高分子量的HMPDE在不同的聚合物/DNA质量比时对293T细胞的体外荧光素酶的转染表达效率,也使用了对照聚合物PEI 25kDa与DNA在氮磷比为10复合物的基因转染效率。图8展示了含双硫键改性的梳型高分子量阳离子聚合物P(Asp-ss-Al-Az-PDE)-1和P(Asp-ss-Al-Az-PDE)-2,低分子量聚合物L-PDE-N3-1在不同的聚合物/DNA质量比时对HeLa细胞在无血清存在时的荧光素酶转染表达(PEI 25kDa与DNA的氮磷比为10)。这些图说明含双硫键改性的梳型高分子量阳离子聚合物P(Asp-ss-Al-Az-PDE)的复合物的基因转染效率大大高于原料低分子量聚合物L-PDE-N3-1的复合物(2-3个数量级),也高于常用高分子基因载体参照聚合物25kDa PEI的复合物的基因转染效率。结果表明:这类还原敏感性双硫键改性的梳型高分子量阳离子聚合物对293T和HeLa细胞具有很高的转染效率。The comb-shaped high-molecular-weight cationic polymers containing disulfide bonds modified in Examples 8-11 were respectively dissolved in NaCl solution (150mmol/L, pH7.4), filtered and sterilized, and prepared into solutions of corresponding concentrations. Add 50 μL solution containing 1.0 μg plasmid DNA (pcDNA3-Luc is the reporter gene of luciferase) to a 1.5 mL sterile centrifuge tube, add corresponding amount of 50 μL cationic polymer solution according to N/P ratio of 10-50, and DNA Composite, shaking for 5s, the complex was used for cell transfection experiments after standing at 37°C for half an hour. Using 25kDa PEI and 1.8kDa PEI as controls, the in vitro transfection efficiency of the complex on 293T and HeLa cells was compared (after adding the complex and serum-free DMEM medium, transfect at 37°C for 4 hours, and the medium was replaced with 1 mL of complete After DMEM medium, culture was continued at 37°C for 48h). Figure 6 shows the comb-shaped high molecular weight cationic polymer P(Asp-Az-Al-ss-PEI)(Asp-EA) 0.67 modified with disulfide bonds, P(Asp-Az-Al-ss-PEI)( Asp-EA) 0.35 and P(Asp-Az-Al-ss-PEI) at different polymer/DNA mass ratios on the in vitro luciferase transfection expression efficiency of 293T cells. The gene transfection efficiency of the complex of P(Asp-Az-Al-ss-PEI)(Asp-EA) 0.67 is higher than that of the common polymer gene carrier reference polymer 25kDa PEI. Figure 7 shows P(Asp-ss-Al-Az-PDE)-1 and P(Asp-ss-Al-Az-PDE)-2, low molecular weight polymer L-PDE-N 3 -1 and linear high molecular weight The transfection efficiency of HMPDE to 293T cells in vitro luciferase at different polymer/DNA mass ratios, and the gene transfection efficiency of the control polymer PEI 25kDa and DNA at a nitrogen-to-phosphorus ratio of 10 were also used. Figure 8 shows the comb-shaped high molecular weight cationic polymers P(Asp-ss-Al-Az-PDE)-1 and P(Asp-ss-Al-Az-PDE)-2 modified with disulfide bonds, low molecular weight Polymer L-PDE-N 3 -1 was expressed by luciferase transfection in HeLa cells in the absence of serum at different polymer/DNA mass ratios (Nitrogen-Phosphorus ratio of PEI 25kDa to DNA was 10). These figures illustrate that the gene transfection efficiency of complexes containing disulfide bond-modified comb-shaped high-molecular-weight cationic polymer P(Asp-ss-Al-Az-PDE) is much higher than that of the starting low-molecular-weight polymer L-PDE-N The complex of 3 -1 (2-3 orders of magnitude) is also higher than the gene transfection efficiency of the complex of the reference polymer 25kDa PEI of the commonly used high molecular gene carrier. The results showed that this kind of reduction-sensitive disulfide bond-modified comb-shaped high-molecular-weight cationic polymer had high transfection efficiency to 293T and HeLa cells.
实施例15聚合物/DNA复合物在有血清存在时的体外转染效率The in vitro transfection efficiency of
步骤同实施例14,区别在于加入复合物和有10%血清DMEM培养基后在37℃转染4h,培养基换成1mL完全DMEM培养基后在37℃继续培养48h)。图9展示了有血清存在时含双硫键改性的梳型高分子量阳离子聚合物P(Asp-ss-Al-Az-PDE)-1和P(Asp-ss-Al-Az-PDE)-2,低分子量聚合物L-PDE-N3-1在不同的聚合物/DNA质量比时对复合物对293T细胞荧光素酶的转染表达效率。结果表明:在有血清存在时,这类还原敏感性含双硫键改性的梳型高分子量阳离子聚合物复合物对293T细胞的转染效率也较高。The steps were the same as in Example 14, except that the transfection was at 37°C for 4 hours after adding the complex and DMEM medium with 10% serum, and the culture medium was replaced with 1 mL of complete DMEM medium and continued to culture at 37°C for 48 hours). Figure 9 shows the comb-shaped high molecular weight cationic polymers P(Asp-ss-Al-Az-PDE)-1 and P(Asp-ss-Al-Az-PDE)-1 modified with disulfide bonds in the presence of
实施例16聚合物/DNA复合物体外绿色荧光蛋白基因转染效率Example 16 polymer/DNA complex in vitro green fluorescent protein gene transfection efficiency
使用实施例8和实施例11中制得的含双硫键改性的梳型高分子量阳离子聚合物P(Asp-ss-Al-Az-PDE)-1和P(Asp-ss-Al-Az-PDE)-2,P(Asp-Az-Al-ss-PEI)(Asp-EA)0.67,P(Asp-Az-Al-ss-PEI)(Asp-EA)0.35和P(Asp-Az-Al-ss-PEI),P(PPA-cyst-MAm-PDE)-1和P(PPA-cyst-MAm-PDE)-2分别复合质粒DNA pEGFP(绿色荧光蛋白基因)体外转染293T细胞,转染48小时后,用荧光显微镜观察绿色荧光蛋白的表达。结果表明,均能有效转导该细胞。Using the comb-type high molecular weight cationic polymer P(Asp-ss-Al-Az-PDE)-1 and P(Asp-ss-Al-Az modified by disulfide bonds obtained in Example 8 and Example 11 -PDE)-2, P(Asp-Az-Al-ss-PEI)(Asp-EA) 0.67 , P(Asp-Az-Al-ss-PEI)(Asp-EA) 0.35 and P(Asp-Az- Al-ss-PEI), P(PPA-cyst-MAm-PDE)-1 and P(PPA-cyst-MAm-PDE)-2 were respectively combined with plasmid DNA pEGFP (green fluorescent protein gene) to transfect 293T cells in vitro. After 48 hours of transfection, the expression of green fluorescent protein was observed with a fluorescence microscope. The results showed that all of them could effectively transduce the cells.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110020684 CN102174579B (en) | 2011-01-19 | 2011-01-19 | Reducible and biodegradable comb type high polymer gene vector and preparation method of same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110020684 CN102174579B (en) | 2011-01-19 | 2011-01-19 | Reducible and biodegradable comb type high polymer gene vector and preparation method of same |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102174579A true CN102174579A (en) | 2011-09-07 |
CN102174579B CN102174579B (en) | 2013-03-06 |
Family
ID=44517820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110020684 Expired - Fee Related CN102174579B (en) | 2011-01-19 | 2011-01-19 | Reducible and biodegradable comb type high polymer gene vector and preparation method of same |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102174579B (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103059297A (en) * | 2012-12-28 | 2013-04-24 | 武汉大学 | Multifunctional degradable polyasparaginate modified polymer and preparation method thereof |
CN104311830A (en) * | 2014-09-26 | 2015-01-28 | 浙江大学 | Dendritic gene and drug carrier, and preparation and application thereof |
CN106890336A (en) * | 2017-03-01 | 2017-06-27 | 中山大学 | A kind of siRNA drug carrier polymer and preparation method thereof and the application in siRNA targeting conveyings |
CN108264639A (en) * | 2017-12-20 | 2018-07-10 | 湖北工业大学 | A kind of temperature pH dual responsiveness cinnamic acid-poly-asparagine, which is gripped, closes object and its water phase cross-linking method |
CN108531514A (en) * | 2018-04-10 | 2018-09-14 | 暨南大学 | Endogenous hyperbranched poly spermine cationic gene carriers and the preparation method and application thereof |
CN109136271A (en) * | 2018-09-20 | 2019-01-04 | 西北工业大学 | Application of the linear macromolecule of cationic polyvinyl amine as transgene carrier |
CN109384937A (en) * | 2018-09-30 | 2019-02-26 | 广州医科大学 | The hyperbranched polyglycidyl ether derivative and its preparation method and application of chlorin modification |
CN116656745A (en) * | 2023-08-01 | 2023-08-29 | 吉林大学第一医院 | Non-viral gene vector and preparation method and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1316318A2 (en) * | 2001-11-29 | 2003-06-04 | Nippon Shokubai Co., Ltd. | Method of transducing a protein into cells |
CN1743359A (en) * | 2005-06-03 | 2006-03-08 | 中国科学院上海应用物理研究所 | Photochemical Synthesis of Polyethyleneimine Gel |
US20070287681A1 (en) * | 2003-04-03 | 2007-12-13 | Bioneer Corporation | siRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof |
CN101492691A (en) * | 2008-12-25 | 2009-07-29 | 华东师范大学 | Assembly method for core-shell structural gene support system and uses thereof |
CN101638484A (en) * | 2009-08-24 | 2010-02-03 | 中国科学院长春应用化学研究所 | Polyethylene glycol monomethyl ether-poly 2-methyl-carboxyl propylene carbonate graft polyethyleneimine copolymer, preparation method thereof and application thereof |
-
2011
- 2011-01-19 CN CN 201110020684 patent/CN102174579B/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1316318A2 (en) * | 2001-11-29 | 2003-06-04 | Nippon Shokubai Co., Ltd. | Method of transducing a protein into cells |
US20070287681A1 (en) * | 2003-04-03 | 2007-12-13 | Bioneer Corporation | siRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof |
CN1743359A (en) * | 2005-06-03 | 2006-03-08 | 中国科学院上海应用物理研究所 | Photochemical Synthesis of Polyethyleneimine Gel |
CN101492691A (en) * | 2008-12-25 | 2009-07-29 | 华东师范大学 | Assembly method for core-shell structural gene support system and uses thereof |
CN101638484A (en) * | 2009-08-24 | 2010-02-03 | 中国科学院长春应用化学研究所 | Polyethylene glycol monomethyl ether-poly 2-methyl-carboxyl propylene carbonate graft polyethyleneimine copolymer, preparation method thereof and application thereof |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103059297A (en) * | 2012-12-28 | 2013-04-24 | 武汉大学 | Multifunctional degradable polyasparaginate modified polymer and preparation method thereof |
CN104311830A (en) * | 2014-09-26 | 2015-01-28 | 浙江大学 | Dendritic gene and drug carrier, and preparation and application thereof |
CN104311830B (en) * | 2014-09-26 | 2017-02-22 | 浙江大学 | Dendritic gene and drug carrier, and preparation and application thereof |
CN106890336A (en) * | 2017-03-01 | 2017-06-27 | 中山大学 | A kind of siRNA drug carrier polymer and preparation method thereof and the application in siRNA targeting conveyings |
CN108264639B (en) * | 2017-12-20 | 2020-08-07 | 湖北工业大学 | A temperature-pH dual-responsive cinnamic acid-polyasparagine conjugate and its water-phase crosslinking method |
CN108264639A (en) * | 2017-12-20 | 2018-07-10 | 湖北工业大学 | A kind of temperature pH dual responsiveness cinnamic acid-poly-asparagine, which is gripped, closes object and its water phase cross-linking method |
CN108531514A (en) * | 2018-04-10 | 2018-09-14 | 暨南大学 | Endogenous hyperbranched poly spermine cationic gene carriers and the preparation method and application thereof |
CN108531514B (en) * | 2018-04-10 | 2020-08-07 | 暨南大学 | Endogenous hyperbranched polyspermine cationic gene carrier and its preparation method and application |
CN109136271A (en) * | 2018-09-20 | 2019-01-04 | 西北工业大学 | Application of the linear macromolecule of cationic polyvinyl amine as transgene carrier |
CN109136271B (en) * | 2018-09-20 | 2021-07-20 | 西北工业大学 | Application of Cationic Polyvinylamine Linear Polymers as Transgenic Carriers |
CN109384937A (en) * | 2018-09-30 | 2019-02-26 | 广州医科大学 | The hyperbranched polyglycidyl ether derivative and its preparation method and application of chlorin modification |
CN109384937B (en) * | 2018-09-30 | 2022-04-05 | 广州医科大学 | Dihydro porphin modified hyperbranched polyglycidyl ether derivative and preparation method and application thereof |
CN116656745A (en) * | 2023-08-01 | 2023-08-29 | 吉林大学第一医院 | Non-viral gene vector and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN102174579B (en) | 2013-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhou et al. | Highly branched poly (β-amino ester) s for skin gene therapy | |
CN102174579A (en) | Reducible and biodegradable comb type high polymer gene vector and preparation method of same | |
Hörtz et al. | Cylindrical brush polymers with polysarcosine side chains: a novel biocompatible carrier for biomedical applications | |
CN108542885B (en) | Antitumor drug and preparation method thereof | |
Li et al. | Well-defined reducible cationic nanogels based on functionalized low-molecular-weight PGMA for effective pDNA and siRNA delivery | |
Wang et al. | The self-assembly of biodegradable cationic polymer micelles as vectors for gene transfection | |
Sun et al. | The strategy to improve gene transfection efficiency and biocompatibility of hyperbranched PAMAM with the cooperation of PEGylated hyperbranched PAMAM | |
Morris et al. | Folate mediated histidine derivative of quaternised chitosan as a gene delivery vector | |
Mathew et al. | Hyperbranched PEGmethacrylate linear pDMAEMA block copolymer as an efficient non-viral gene delivery vector | |
CN103059291B (en) | Poly (gamma-oligomerization ethylene glycol monomethyl ether-L-glutamic acid diethyl ester) - polyamino acid diblock copolymer and preparation method thereof | |
CN101812178B (en) | Reduction sensitive polyethyleneimine derivative as well as preparation method and application thereof | |
Ren et al. | Charge density and molecular weight of polyphosphoramidate gene carrier are key parameters influencing its DNA compaction ability and transfection efficiency | |
Morris et al. | Folate mediated in vitro targeting of depolymerised trimethylated chitosan having arginine functionality | |
EP2070970B1 (en) | Transfection Reagent | |
Chen et al. | Multi‐armed poly (L‐glutamic acid)‐graft‐oligoethylenimine copolymers as efficient nonviral gene delivery vectors | |
Lin et al. | Cationic micellar nanoparticles for DNA and doxorubicin co-delivery | |
CN113929904A (en) | Functional single-chain cyclic poly (beta-amino ester), preparation method thereof and application of gene delivery drug | |
Zeng et al. | A novel dendrimer based on poly (L-glutamic acid) derivatives as an efficient andbiocompatible gene delivery vector | |
Sajomsang et al. | Methylated N-aryl chitosan derivative/DNA complex nanoparticles for gene delivery: Synthesis and structure–activity relationships | |
Xu et al. | Dendron‐like poly (ε‐benzyloxycarbonyl‐l‐lysine)/linear PEO block copolymers: Synthesis, physical characterization, self‐assembly, and drug‐release behavior | |
Johnson et al. | Poly (2‐Hydroxyethyl Methacrylate)‐b‐Poly (L‐Lysine) Cationic Hybrid Materials for Non‐Viral Gene Delivery in NIH 3T3 Mouse Embryonic Fibroblasts | |
Dong et al. | Cross-linked polyethylenimine as potential DNA vector for gene delivery with high efficiency and low cytotoxicity | |
CN104086721B (en) | Poly-(Pidolidone-γ-hydrazides)-PDMAPMA triblock copolymer of mPEG-and synthetic method thereof and application | |
Xu et al. | Novel poly (ethylene imine) biscarbamate conjugate as an efficient and nontoxic gene delivery system | |
CN102464801A (en) | A kind of cationic polymer and its preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130306 Termination date: 20170119 |
|
CF01 | Termination of patent right due to non-payment of annual fee |